IMMUNOGENIC COMPOSITIONS

专利摘要:
The present invention relates to the field of native outer membrane vesicles (nOMV), in particular nOMVs having increased levels of lipoproteins on their surface and their use in immunogenic compositions.
公开号:BE1024794B1
申请号:E2017/5464
申请日:2017-06-29
公开日:2018-07-10
发明作者:Beatrice Ricchetti；Isabel Delany
申请人:Glaxosmithkline Biologicals Sa；
IPC主号:

专利说明:

(73) Holder (s):
GLAXOSMITHKLINE BIOLOGICALS SA
1330, RIXENSART
Belgium (72) Inventor (s):
RICCHETTI Beatrice 53100 SIENA Italy
DELANY Isabel 53100 SIENA Italy (54) IMMUNOGENIC COMPOSITIONS (57) The present invention relates to the field of native external membrane vesicles (nOMV), in particular nOMVs having increased levels of lipoproteins on their surface and their use in immunogenic compositions.
t L: · <.
BELGIAN INVENTION PATENT
FPS Economy, SMEs, Middle Classes & Energy
Publication number: 1024794 Deposit number: BE2017 / 5464
Intellectual Property Office International Classification: C12N 1/21 C12N 9/14 A61K 35/74 A61K 39/095 C12R 1/36 Date of issue: 07/10/2018
The Minister of the Economy,
Having regard to the Paris Convention of March 20, 1883 for the Protection of Industrial Property;
Considering the law of March 28, 1984 on patents for invention, article 22, for patent applications introduced before September 22, 2014;
Given Title 1 “Patents for invention” of Book XI of the Code of Economic Law, article XI.24, for patent applications introduced from September 22, 2014;
Having regard to the Royal Decree of 2 December 1986 relating to the request, the issue and the maintenance in force of invention patents, article 28;
Given the patent application received by the Intellectual Property Office on June 29, 2017.
Whereas for patent applications falling within the scope of Title 1, Book XI of the Code of Economic Law (hereinafter CDE), in accordance with article XI. 19, §4, paragraph 2, of the CDE, if the patent application has been the subject of a search report mentioning a lack of unity of invention within the meaning of the §ler of article XI.19 cited above and in the event that the applicant does not limit or file a divisional application in accordance with the results of the search report, the granted patent will be limited to the claims for which the search report has been drawn up.
Stopped :
First article. - It is issued to
GLAXOSMITHKLINE BIOLOGICALS SA, Rue de l'Institut 89, 1330 RIXENSART Belgium;
represented by
PRONOVEM - Office Van Malderen, Avenue Josse Goffin 158, 1082, BRUXELLES;
a Belgian invention patent with a duration of 20 years, subject to payment of the annual fees referred to in article XI.48, §1 of the Code of Economic Law, for: IMMUNOGENIC COMPOSITIONS.
INVENTOR (S):
RICCHETTI Beatrice, c / o GlaxoSmithKline Via Fiorentina 1,53100, SIENA;
DELANY Isabel, c / o GlaxoSmithKline Via Fiorentina 1, 53100, SIENA;
PRIORITY (S):
06/29/2016 EP 16177013.6;
DIVISION:
divided from the basic application: filing date of the basic application:
Article 2. - This patent is granted without prior examination of the patentability of the invention, without guarantee of the merit of the invention or of the accuracy of the description thereof and at the risk and peril of the applicant (s) ( s).
Brussels, 07/10/2018, By special delegation:
BE2017 / 5464
IMMUNOGENIC COMPOSITIONS
Technical area
The present invention relates to the field of vesicles of native outer membrane (nOMV), particularly nOMV having increased levels of lipoproteins on their surface and their use in immunogenic compositions. The invention further relates to novel genetically modified Gram negative bacterial strains and their use in the preparation and manufacture of nOMV.
Context of the invention
Gram negative bacteria spontaneously release bleb-like particles from the outer membrane of the cell wall known as native outer membrane vesicles (nOMV) [1]. The outer membrane vesicles can also be produced artificially, for example, by extraction with a detergent (qualified as dOMV). Outer membrane vesicles can also be produced from genetically engineered bacteria to exhibit a "hyperbleb" phenotype in which, as a result of the genetic modification, large amounts of outer membrane sprout, thereby providing a practical source of membrane material. OMVs extracted by a detergent differ from nOMVs because the required detergent removes membrane components such as lipoproteins and increases the cost of producing dOMVs compared to nOMVs. While nOMVs can
BE2017 / 5464 be isolated from the culture medium, generally the quantities produced are too small to be practical for commercial production of vaccines.
Expression of complex outer membrane proteins in their native conformation and correct orientation in nOMVs provides significant potential advantages over recombinant proteins. To induce the formation of nOMVs to provide larger quantities sufficient for commercial vaccine production, the membrane structure is modified by deletion of genes coding for key structural components, for example gna33 (meningococcus) or tolR (Shigella and Salmonella ) [2]. Unlike vaccines based on whole bacteria, nOMVs lack the internal membrane and cytoplasmic components which are rarely the targets of protective immunity. Since nOMVs, particularly nOMVs isolated from "hyperbleb" bacteria, are particularly suitable for the development of vaccines, an object of the invention is to provide methods for the production of nOMVs having improved characteristics and qualities.
Brief description of the invention
In a first aspect, the invention provides a Gram negative bacterium which overexpresses, constitutively expresses or inducibly expresses a flippase. The bacteria can be "hyperbleb". In particular, the Gram negative bacterium is chosen from the group consisting of Neisseria, Salmonella, Shigella,
BE2017 / 5464
Haemophilus, Bordetella, Moraxella, Chlamydia and Escherichia. Even more particularly, the Gram negative bacterium is chosen from the group consisting of Neisseria meningitidis, Neisseria gonorrhoeae, Salmonella typhi, Salmonella typhimurium, Shigella flexneri, Shigella dysenteriae, Shigella boydii, Shigella sonnei, Haemophilus influenzae, Bordetella pertussis, Bordetella pertussis Escherichia coli.
The term "hyperbleb", as used herein, refers to a mutant strain of bacteria which spontaneously releases vesicles from the outer membrane in larger amounts than a wild type or parent strain from which it was derived (for example, per unit of time). In general, "hyperblebs" mutants release larger amounts of outer membrane vesicles than the wild-type or parent strain from which they were derived, for example, more than 10%, more than 20%, more than 30% or more than 40%. Gram negative "hyperbleb" bacteria may be a naturally occurring mutant strain or they may be genetically engineered to exhibit a "hyperbleb" phenotype. The term "wild type" refers to bacteria which does not refer to bacteria. has not been modified either chemically or genetically in any way (other than developed in a culture medium). In particular, a "wild type" bacterium is a bacterium that has not been genetically modified to increase the release of vesicles from the outer membrane. On the contrary, the term
BE2017 / 5464 "modified" or "mutant" refers to a bacterium, a gene or a gene product that displays changes in the sequence and / or properties (i.e., modified characteristics) when compared to the bacteria, gene or wild type gene product. It is noted that naturally occurring mutants can be isolated; these are identified by the fact that they exhibit altered characteristics (including altered nucleic acid sequences) when compared to the bacteria, gene or wild type gene product.
The term "constitutively expresses" refers to the continuous expression of a gene of interest without any regulation (transcription is neither suppressed nor induced). Rather, the term "inducibly expresses" refers to the regulated of a gene of interest in
The expression laguelle transcription occurs in response to an inducer. The term “overexpressed” is used to induce a rate of expression which is greater than that generally observed in a control bacterium, of wild type and / or non-transgenic. In particular, with reference to the levels of mRNA which can be measured using one of a number of techniques known to those skilled in the art including, but not limited to, Northern blot analysis and / or the real-time guantitative polymerase chain reaction (gRT-PCR).
Neissian strains, such as Neisseria meningitidis or Neisseria gonorrhoeae, can be genetically modified to present a phenotype
BE2017 / 5464 "hyperbleb" by negative regulation or abolition of the expression, by way of nonlimiting example, of GNA33. Similar mutations are known in other bacteria, for example, strains of Haemophilus influenza, Moraxella catarrhalis and Escherichia coli can be genetically engineered to exhibit a "hyperbleb" phenotype by downregulation or suppression of the expression of one or several genes selected from the group consisting of tolQ, tolR, tolX, tolA and tolB. The strains of Shigella flexneri, Shigella dysenteriae, Shigella boydii and Shigella sonnei can be genetically modified to present a “hyperbleb” phenotype by negative regulation or abolition of the expression of one or more of tolR or OmpA. Mutations suitable for down regulation or expression abolition include gene deletions, and any modification of the genomic sequences which results in a change in gene expression, particularly a reduction and more particularly an inactivation or silencing . Other suitable mutations are known in the art.
In some embodiments, the Gram-negative "hyperbleb" bacterium is genetically modified by mutation to reduce the pyrogenic potential of the lipopolysaccharide (LPS) in bacteria. Particular mutations include, by way of nonlimiting example, mutations in IpxLl, synX, IgtA, htrA, msbBl, msbB2, virG and their counterparts. Mutations suitable for negative regulation or point mutations, gene insertions,
BE2017 / 5464 abolishment of expression include point mutations, gene deletions, gene insertions, and any modification of genomic sequences which results in a change in gene expression, particularly a reduction and even more particularly inactivation or silencing. Preferably, the mutation is a deletion. Other suitable mutations are known in the art.
The Gram-negative "hyperbleb" bacterium can also be genetically modified by one or more methods chosen from the following group: (a) a method of negative regulation of the expression of variable or non-protective immunodominant antigens, (b) a method of upregulation of the expression of protective OMP antigens, (c) a method of downregulation of a gene involved in making the lipid A portion of LPS toxic, (d) a method of upregulation of a gene involved in making the lipid A part of the less toxic LPS, and (e) a method of genetic modification of the bacteria to express a heterologous antigen.
In particular, the flippase comprises a sequence having 80% of sequence identity with,
or who East a counterpart of, a sequence chosen in the group made of SEQ ID NO: 1, SEQ ID NO : 2, SEQ ID NO: 3 and SEQ ID NO: 4. In a way again more
particular, the flippase comprises a sequence having more than 85%, more than 90%, more than 95%, more than 96%, more than 97%, more than 98% or more than 99% of identity with a sequence chosen from the group
BE2017 / 5464 consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4. In certain embodiments, the flippase comprises a sequence chosen from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4.
In a second aspect of the invention, there is provided a preparation of the outer membrane vesicles obtained from the bacteria of the first aspect. The outer membrane vesicles obtained from such a bacterium have a level or a greater amount of at least one lipoprotein exposed on the surface, for example, as measured by a FACS analysis and during a comparison with the vesicles of outer membrane obtained from a wild type or parent strain. In particular, the outer membrane vesicles can be filtered through a 0.22 µm membrane.
In a third aspect of the invention there are provided pharmaceutical compositions comprising the preparation of outer membrane vesicles of the second aspect of the invention. In particular, the pharmaceutical composition comprises a diluent or a pharmaceutically acceptable carrier. More particularly, the pharmaceutical composition is intended for use in a method of treatment of the human or animal body. Preferably, the pharmaceutical composition is a vaccine composition.
A fourth aspect of the invention provides a method of protecting, preventing or treating an individual against a bacterial infection which
BE2017 / 5464 comprises the administration to the individual of an effective amount of outer membrane vesicles of the second aspect or of the pharmaceutical composition of the third aspect. In particular, the individual is a mammal, preferably a human. The bacterial infection may correspond to the genus and / or species from which OMV was obtained (for example, an OMV derived from Neisseria meningitidis used to protect, prevent or treat an infection by Neisseria meningitidis) . When present, the one or more heterologous outer membrane proteins may or may not correspond to the genus and / or species from which OMV was obtained. The bacterial infection may correspond to the genus and / or species from which one or more heterologous outer membrane proteins were obtained or derived (for example, the outer membrane protein derived from Neisseria meningitidis used for protect, prevent, or treat Neisseria meningitidis infection). The species from which OMV was obtained may or may not correspond to the bacterial infection. In one embodiment, the species from which OMV was obtained and the one or more heterologous proteins correspond to the bacterial infection.
According to a fifth aspect, there is provided a method of preparing a pharmaceutical composition comprising a preparation of outer membrane vesicles of the second aspect, the method comprising: (a) inoculating a culture vessel containing a suitable nutrient medium for the growth of
BE2017 / 5464 bacteria of the first aspect; (b) culturing said bacteria; (c) recovering the outer membrane vesicles from the medium; and (d) mixing the outer membrane vesicles with a pharmaceutically acceptable diluent or carrier. In some embodiments, the method may further comprise a step, after either step (c) or step (d), comprising sterilizing the preparation of outer membrane vesicles by filtration. In particular, the filtration step comprises at least one tangential flow filtration (FFT) step. Even more particularly, the method does not use centrifugation.
In a sixth aspect, there is provided a method of producing a "hyperbleb" bacterium according to the fifth aspect, which method comprises the genetic modification of a Gram negative bacterial strain by: (a) modifying the strain to negatively regulate the expression of one or more Toi genes; and (b) modification of the strain to overexpress, express constitutively or express inducibly a flippase. Steps (a) and (b) of the method can be carried out in any order or they can be carried out substantially at the same time.
Brief description of the figures
Figure 1 - (A) Schematic representation of the predicted structural domains of NMB0313 (BLASTP 2.3.1);
(B) schematic representation of the knockout strategy (inactivation) of nmb0313.
BE2017 / 5464
Figure 2 - Western blot analysis of NMB0313 expression in wild type and knockout strains (inactivated) for nmb0313 (i) MC58, (ii) NGH38 and (irr) NZ 98/254.
Figure 3 - Analysis of the expression and exposure on the surface of the fHbp and NHBA lipoproteins in nmb0313KO strains by Western blot and FACS analysis.
Figure 4 - (A) Schematic representation of the genomic complementation strategy by nmb0313; (B) Western blot analysis of the expression of NMB0313 in increasing concentrations of IPTG.
Figure 5 - Analysis of the expression and exposure on the surface of the fHbp and NHBA lipoproteins in the NGH38 strain supplemented with nmb0313 by
A) Western blot and FACS analysis; B) on the diagrams, the percentages of the average fluorescence (IMF) extrapolated from the FACS analysis of fHbp or NHBA are reported relative to the wild-type rates (wt) at the different IPTG concentrations.
Figure 6 - A) Schematic representation of the plasmids used for the transformation of E. coli;
B) Western blot analysis of the recombinant expression of NMB0313 and fHbp in the presence of increasing concentrations of IPTG and FACS analysis of fHbp; C) on the diagrams, the MFIs extrapolated from the FACS analysis of fHbp are reported at the different concentrations of IPTG; D) western blot analysis of the recombinant expression of NHBA and FACS analysis of NHBA (preliminary results).
BE2017 / 5464
Figure 7 - Schematic representation of the Cola DUET pet plasmids with NMB0313, and fHBP or NHBA, cloned in one of the two multiple cloning sites.
Figure 8 - Western blot analysis of E. lysates. coli after culture in 0.1 mM of IPTG stained with a polyclonal serum A) anti-fHbp and B) anti-NHBA from cultures carrying pETCOLA alone (empty) or pETCOLA expressing one or the other lipoprotein alone ( NHBA or fHbp, respectively) or coexpressing lipoprotein chague with NMB0313 (NHBA 0313 or fHbp 0313, respectively). FACS analysis on the respective cultures including E. coli expressing NMB0313 alone (0313) using an antibody (C) α-NHBA and (D) a-fHbp.
Figure 9-4 pg of OMV were loaded onto an SDS-PAGE gel and the bands relating to NMB0313 (pink), NHBA (green) and fHBP (red) are highlighted.
Figure 10 - Western blot using a polyclonal antibody a-fHbp of a serial dilution of OMV of E. coli starting at 1 pg.
Figure 11 - Outline of the immunization schedule.
Figure 12 - ELISA titers using recombinant fHbp as the sensitizing antigen. Statistical analysis was performed using the Kruskal-Wallis multiple comparison test (ns: not significant; ** p <0.0065; *** p <0.0009, **** p <0, 0001 ).
Figure 13 - Titers of rSBA with pooled mouse sera.
BE2017 / 5464
Figure 14 - rSBA with simple mice. Statistical analysis was performed using the Kruskal-Wallis multiple comparison test (** p <0.0024, **** p <0.0001).
Figure 15 - ELISA titers using α-NHBA as an awareness antigen. Statistical analysis was performed using the test of
comparisons multiple of Kruskal-Wallis (ns: no significant ; ** p <0, 0 0 60; *** p <0.0002). Figure 16 - Titles of rSBA of pooled sera from groups indicated 1 (OMV empty 2 pg), 2 (OMV 0313
pg), 8 (OMV NHBA 2 pg), 9 (OMV NHBA + 0313 2 pg), and 10 (rNHBA 1 pg).
Figure 17 - rSBA with simple mice. Statistical analysis was performed using the Kruskal-Wallis multiple comparison test (** p <0.0051).
Figure 18 - Western blot analysis of N. meningitis lysates stained with antiNHBA polyclonal serum A) anti-NMB0313 and B) anti-fHbp, from liquid cultures. The complemented strain NGH38 (C10313) is cultivated with different concentrations of IPTG.
C) The FACS analysis of fHbp or NHBA on the respective cultures is reported in the form of diagrams with the percentage of mean fluorescence (IMF) extrapolated from the FACS analysis.
Figure 19 - A) 4 μg of OMV are loaded onto an SDS-PAGE gel. B) WB analysis of 1 μg of OMV stained with an α-fHbp polyclonal serum and an aNHBA polyclonal serum.
Figure 20 - rSBA with pooled mouse sera.
BE2017 / 5464
Figure 21 - Raw data from example B.
Detailed description of the invention
The inventors have discovered that the coexpression of a flippase in a bacterial cell with at least one lipoprotein of interest (such as the factor H binding protein (fHbp)) strongly influences the total amount of the lipoprotein of interest and / or the proportion of the lipoprotein of interest that is exposed at the surface. The inventors have further discovered that Gram negative bacterial cells coexpressing a flippase and at least one lipoprotein of interest can be used to produce external membrane vesicles which are enriched in said at least one lipoprotein of interest. Such OMVs (sometimes qualified as generalized modules for membrane antigens or GMMA) isolated from such Gram negative bacterial cells are particularly suitable for use in immunogenic compositions such as vaccines. To avoid ambiguity, the reference to OMV or GMMA is intended to refer to vesicles of native outer membrane, particularly vesicles of native outer membrane derived from bacteria which have or display a “hyperbleb” phenotype and do not detergent outer membrane vesicles .
The outer membranes of Gram negative bacteria are immunologically important structures due to their accessibility to host defense mechanisms. Lipoproteins are proteins not including those extracted with a
BE2017 / 5464 characterized by the presence of a lipid cysteine which allows the anchoring of the molecule to the membrane. Preferably, the at least one lipoprotein of interest is attached to the extracellular side of the outer membrane. Even more particularly, the at least one lipoprotein of interest is an immunogenic lipoprotein. Thus, the term "exposed on the surface" is used to mean that lipoproteins are available for antibody binding (for example, on the outer layer of the outer membrane of bacterial cells and / or OMV). Thus, the OMVs of the invention comprise more than at least one lipoprotein of interest and / or an increased proportion and / or amount of the at least one lipoprotein of interest which is exposed on the surface.
The term "enriched" refers to a compound or composition which has an increased proportion of a desired property or element. For example, an OMV or GMMA which is "enriched" for a lipoprotein means that the OMV or GMMA comprises a
proportion superior of the lipoprotein (by example, more than 50 %, 55%, 60 OGold 65 %, 70%, 75% , 80 %, 85%, 90%, 95% or more up ' at 100%) and / or a fraction
greater (greater than 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 5.5 times or more) in total lipoprotein and / or a greater fraction (greater than 1.25 , 1.5, 2, 2.5, 3, 3.5, 4, 5, 5.5 or more times) of lipoprotein exposed on the surface compared to an OMV or GMMA derived from a cell which does not overexpress , does not express constitutively or has not been induced to express flippase.
BE2017 / 5464 factor H identified
This is advantageous because lipoproteins are capable of activating an immune response in the host ranging from the production of bactericidal antibodies to the production of a cytotoxic T lymphocyte response. For example, the binding protein of (fHbp) is a 28 kD lipoprotein as a protective antigen against
Neisseria meningitidis which is capable of triggering a bactericidal response independent of PorA displaying a largely crossed reactivity. Improvements in the exposure or quantity of lipoproteins on the surface of outer membrane vesicles, particularly GMMAs, can lead to improvements in the immune response obtained following vaccination. In addition, the coexpression of a flippase can also facilitate exposure to the surface of heterologously expressed lipoproteins. Thus, the invention also has the potential to help save doses, reducing the amount of the outer membrane vesicle component required in a pharmaceutical or vaccine composition to induce a desired immune response, thereby reducing the risk, for example , pyrogenicity.
Bacteria
The invention can be applied to various Gram negative bacteria, such as species of any of the genera Escherichia, Shigella, Neisseria, Moraxella, Bordetella, Borrelia, Brucella, Chlamydia, Haemophilus, Legionella, Pseudomonas, Yersinia, Helicobacter, Salmonella , Vibrio, and the like. For example, the
BE2017 / 5464 bacteria can be Bordetella pertussis, Borrelia burgdorferi, Brucella melitensis. Brucella ovis, Chlamydia psittaci, Chlamydia trachomatis, Moraxella catarrhalis, Escherichia coli, Haemophilus influenzae (including strains not
Legionella
Neisseria
Pseudomonas
Helicobacter typables), gonorrhoeae, lactamica, pneumophila, meningitidis, aeruginosa,
Neisseria
Neisseria
Yersinia enterocolitica, pylori, Salmonella enterica (including serovars typhi and typhimurium, as well as serovars paratyphi and enteritidis), Vibrio cholerae, etc.
The invention is particularly suitable for use with Neisseria (such as Neisseria meningitidis or Neisseria gonorrhoeae), Salmonella (such as Salmonella typhi or Salmonella typhimurium), Shigella (such as S. dysenteriae, S. flexneri, S. boydii or S. sonnei), Escherichia coli (including extra-intestinal pathogenic strains), Haemophilus influenzae (for example, non-typable Haemophilus influenzae or NtHI) and Bordetella pertussis.
Gram negative bacteria spontaneously release the outer membrane vesicles during bacterial growth and these can be purified from the culture medium. In preferred embodiments, the bacteria for use in the invention are, relative to their corresponding wild-type strains, "hyperbleb", that is, they release into their culture medium further larger amounts of outer membrane vesicles than the wild type strain. Naturally occurring "hyperblebs" strains for
BE2017 / 5464 a use in the invention are known in the art, for example, the strain of N. gonorrhoeae WR302. In some embodiments, the bacteria are genetically engineered to release larger amounts of outer membrane vesicles or GMMA into the culture medium during the growth and replication of the bacterial cells. The particular genes or proteins known to modify vesiculation include, by way of nonlimiting example, GNA33, ompA, degP, degS, nlpl, ompC, ompR, pnp, ponB, rmpM, rseA, tatC, tolA, tolQ, tolR , tolB, pal, wag / rfaG, wzxE, yleM and their counterparts.
In certain embodiments, at least one of the proteins known to modify vesiculation is eliminated, for example, by deletion or inactivation of the gene. Methods suitable for deleting or inactivating genes are known in the art. In other embodiments, overexpression of particular genes / proteins such as the N-terminal domain of phage protein g3P or the translocation domains of colicins A and E3 can lead to increased vesiculation. Suitable methods for expressing, particularly overexpressing, genes / proteins are known in the art.
Flippases
Flippases are proteins that transmit transmembrane lipids located in the cell membrane and are responsible for helping the movement of phospholipid molecules between or across the cell membrane. Thus, the flippases of the present invention are lipid transporters
BE2017 / 5464 (lipoproteins) with the ability to move or facilitate the movement (for example, as part of a multifactorial process) of one or more lipoproteins to the extracellular side of the outer membrane.
An example of flippase involved in the surface exposure of N. meningitidis lipoproteins has been identified and is encoded by the nmb0313 gene. It is a protein of the outer membrane characterized by the presence of an N-terminal domain with a tetratricopeptide repeat domain (TRP) and a C-terminal transmembrane domain structured as a porine type domain. The nucleic and amino acid sequences of nmb0313 are provided as SEQ ID NO: 1 and SEQ ID NO: 2, respectively. The amino acid sequence of another N. meningitidis flippase, nmbl971, is provided in the form of SEQ ID NO: 3. Flippase homologs of Streptococcus pneumoniae and Haemophilus influenzae have also been identified and are provided in the form of SEQ ID NO: 4 and SEQ ID NO: 5, respectively
In certain embodiments of the invention, the Gram negative bacterium is genetically modified to inducibly express at least one flippase (derived from a strain which does not naturally express a flippase or, alternatively, derived from a strain that naturally expresses flippase (for example, in replacement of or in addition to naturally expressed flippase)). In an inducible expression system, expression of the coding sequence for flippase occurs in the bacterial cell in
BE2017 / 5464 response to an applied stimulus, for example, in response to contact with an expression-mediating compound such as, by way of nonlimiting example, IPTG. Thus, in some embodiments, the Gram negative bacteria is genetically engineered to include an inducible expression cassette which is sensitive to a transcription modulator configured in such a way that inducible expression of a coding sequence is obtained. of flippase. In other embodiments of the invention, the Gram-negative bacterium is genetically engineered to constitutively express at least one flippase such that expression of a flippase coding sequence in a Gram-negative bacterial cell is continuous regardless of the presence or absence of a mediating component of the particular expression. The term "overexpressed" or "overexpressed" refers to the expression of a gene product at a rate greater than that expressed before handling the microorganism or in a comparable microorganism that has not been manipulated. Thus, the microorganism can be genetically engineered or modified to overexpress a level of flippase higher than that expressed in a comparable microorganism that has not been modified. Genetic engineering may include, but is not limited to, the alteration or modification of regulatory sequences or sites associated with the expression of a particular gene (for example, by the addition of strong promoters, promoters inducible or multiple promoters or by eliminating regulatory sequences such that expression is
BE2017 / 5464 constitutive), changing the chromosomal location of a particular gene, changing the nucleic acid sequences adjacent to a particular gene such as a ribosome binding site, increasing the number of copies of a particular gene, modification of proteins (eg, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and / or translation of a particular gene product , or any other traditional means of deregulation of expression of a particular gene routine in the art (including, but not limited to, the use of antisense nucleic acid molecules, for example, to block the expression of repressor proteins). Genetic engineering can also include the deletion of a gene, for example, to block a pathway or to eliminate a repressor. The flippase can be a heterologous flippase. The term "heterologous flippase" refers to a flippase gene which is either foreign to a chosen host cell or is otherwise modified (for example, a native gene placed under the control of a different promoter). For example, a heterologous nucleic acid may be a nucleic acid which is normally found in the reference organism at a different genomic location or it may be a nucleic acid which is not normally found in the reference organism. A Gram negative bacterium comprising a heterologous flippase can be produced by introduction of the polynucleotide or gene sequence of the flippase
BE2017 / 5464 in Gram negative bacteria. In particular examples, the polynucleotide sequence of a heterologous flippase comprises a native coding sequence, or one of its parts, which is reintroduced into a Gram negative bacterium in a form which is different from the corresponding native polynucleotide. For example, a polynucleotide sequence of a heterologous flippase may include a native coding sequence which is a part of a chimeric gene comprising non-native regulatory regions which is reintroduced into the native Gram negative bacteria.
Outer membrane vesicles or GMMA
OMV or GMMA generally have a diameter of 35 to 120 nm by electron microscopy, for example, 50 nm in diameter. OMV or GMMA released during bacterial growth can be purified from the culture medium. Purification ideally involves the separation of GMMAs from living and / or intact bacteria, for example, by size-based filtration using a filter, such as a 0.22 µm filter, which allows GMMAs to pass through but which does not allow intact bacteria to pass through, or by the use of low speed centrifugation to aggregate cells while leaving GMMA in suspension. Appropriate purification methods are known in the art. A preferred two-stage filtration purification process is described in WO 2011/036562 incorporated herein by reference. In particular, the two-stage filtration process
BE2017 / 5464 is used to separate GMMA from biomass of cell culture without the use of centrifugation.
The compositions of the invention containing OMV or GMMA will generally be substantially free of whole bacteria, whether living or dead. The size of GMMA means that they can be easily separated from whole bacteria by filtration, for example, such as is generally used for sterilization on a filter. Although the GMMAs pass through the conventional 0.22 µm filters, these can quickly become clogged with other materials, and so it may be useful to carry out sequential sterilization steps on the filter through a series filters of decreasing pore size before using a 0.22 µm filter. Examples of the above filters will be those with a pore size of 0.8 µm, 0.45 µm, etc. GMMAs are released spontaneously from bacteria and separation from the culture medium, for example, using filtration, is practiced. The outer membrane vesicles formed by mistletoe processes involve deliberate rupture of the outer membrane (for example, by treatment with a detergent, such as extraction with deoxycholate, or sonication) to induce the formation of the membrane vesicles external are excluded from the scope of the invention. Preferably, the OMV or GMMA used in the invention are substantially free of internal membrane and cytoplasmic contamination and they contain lipids and proteins.
BE2017 / 5464
Modification of the structure of lipid A
Of preferably OMV or GMMA are prepared for go of bacteria Gram negative presenting a genetic modification who grows the bacteria to produce a lipopolysaccharide (LPS) who is changed
to have reduced toxicity. Preferably, the Gram negative bacterium produces LPS with reduced toxicity in which the LPS (or its lipid fraction A (LA)) is modified to have reduced toxicity. An LPS which is modified to have reduced toxicity is understood herein as an LPS which is modified to exhibit less toxicity than the toxicity of a corresponding wild type LPS. Preferably, the modified LPS has less than about 90, 80, 60, 40, 20, 10, 5, 2,
1, 0.5, or 0.2% of the toxicity of the corresponding wild-type LPS. The toxicities of wild type LPS and various LPS modified with reduced toxicity can be determined in any suitable test known in the art. A preferred test for determining the toxicity, ie the biological activity of LPS, is the WEHI test for the induction of TNF-alpha in the MM6 macrophage cell line [43, 44].
However, while it is preferred that the LPS of the Gram negative bacteria (or its LA fraction) has reduced toxicity, it is further preferred that the LPS retains at least part of its immunostimulatory activity, that is to say - to say, its adjuvant activity. Thus, the LPS with reduced toxicity of the Gram negative bacterium to be used in the invention preferably has at least about 10, 20, 40, 80, 90 or 100% of the immunostimulatory activity of the wild-type LPS.
BE2017 / 5464 dendritic costimulant a corresponding gram negative cell molecule, thanks to which the immunostimulatory activity is determined by measuring the production of at least one cytokine or the expression of at least during coculture (CD) with the bacteria producing LPS with reduced toxicity as described in Example 3 of document WO 2005/107798.
The LPS of Gram negative bacteria with reduced toxicity of the lipid A fraction but retaining (part of) the adjuvant activity, can be obtained, for example, from genetically modified Gram negative pathogens and as described in the document. WO 02/09746. Genetically engineered Gram negative pathogens producing LPS with reduced lipid A toxicity but retaining (part of) their adjuvant activity include, for example, Gram negative bacteria with one or more genetic modifications that decrease or inactivate (knock- out) the expression of one or more genes chosen from the genes IpxLl and lpxL2 or their counterparts (formerly known as htrB and msbB; see for example, document WO 00/26384; US Patent No. 5 997 881) and the IpxK gene coding for lipid A 4'-kinase or one of its counterparts (see also below); and genetic modifications that affect the expression of one or more heterologous lpxE and pagL genes. Particular genetic modifications are modifications which decrease or inactivate (knockout) the expression of one or more genes chosen from the genes IpxLl and lpxL2
BE2017 / 5464 or their counterparts. A preferred LPS with reduced toxicity of the lipid A fraction but retaining (part of) its adjuvant activity is an LPS described in document WO 00/26384.
For example, it is known to modify bacteria so that they do not express a native lipopolysaccharide (LPS), particularly for E. coli, meningococcus, Shigella, and the like. Various modifications of native LPS can be made, for example, these can disrupt the structure of native lipid A, the oligosaccharide nucleus, or the external O antigen. Appropriate modifications include deletion or inactivation, by way of nonlimiting example, of IpxL, IpxLl, lpxL2, IpxM, htr, msbBl, msbB2, pagP, IgtA, synX and the like.
Strains suitable for Shigella for use in the invention may include one or more other changes from a wild type strain. In particular, strains for use with the invention include one or more mutations resulting in the inactivation of htrB, msbBl and / or msbB2. By way of nonlimiting example, appropriate mutations can be chosen from the group consisting of AhtrB, AmsbBl and AmsbB2. For simplicity, double deletions of both msbBl and msbB2 can also be qualified as ADmsbB. Inactivation of htrB or msbB1 and msbB2 reduces acylation in lipid A. In some embodiments, the strains for use with the invention lack the O antigen in LPS,
BE2017 / 5464 thereby avoiding specific serotype responses when
In S. sonnei, the antigen the virulence plasmid is other embodiments, strains for use with the invention produce LPS comprising the O antigen. The presence of the O antigen may be advantageous since compositions immunogens will trigger both serotype-specific and additional cross-reactive immune responses. The loss of the virulence plasmid leads to the loss of the msbB2 gene, and the chromosomal gene msbB1 can be inactivated, thereby eliminating myristoyl transferase and
O is absent eliminated. In
The activity providing a penta-acylated lipid A in the LPS. Particular strains of Shigella for use in the invention have a penta-acylated LPS. Alternatively, inactivation of htrB results in the loss of the lauroyl chain and thus can produce penta-acylated LPS in certain strains and / or forms of lipid A which are less toxic than wild type lipid A. For example, in S. flexneri, the inactivation of htrB can be compensated for by the activity of another enzyme, LpxP which produces a hexa-acylated lipid A in which the lauroyl chain is replaced by a palmitoleoyl chain. Hexa-acylated lipid A comprising palmitoleoyl chains is less toxic than wild-type lipid A.
Appropriate strains are disclosed in the examples. Other suitable strains are known in the art, by way of nonlimiting example, in
BE2017 / 5464 documents WO 2006/046143, EP 2279747, WO 2011/036564 and WO 2014/174043.
Lipoproteins of special interest
In particular, the cells of Gram negative bacteria will coexpress at least one flippase and at least one lipoprotein of interest so that the bacterial cells can be used to produce vesicles of external membranes which are enriched in said at least one lipoprotein. interest
The at least one lipoprotein of interest can be a heterologous lipoprotein or a native lipoprotein The term "heterologous lipoprotein" refers to a lipoprotein which is either foreign to a chosen host cell, and / or otherwise is modified (for example, a native gene under the control of a different promoter). For example, the nucleotide sequence of a heterologous lipoprotein may be a nucleotide sequence which is normally found in the reference organism at a different genomic location or may be a nucleic acid which is normally found in the reference organism. A Gram negative bacterium comprising a heterologous lipoprotein can be produced by introducing the polynucleotide or gene sequence of the heterologous lipoprotein into the Gram negative bacterium. In particular examples, the polynucleotide or gene sequence of the heterologous lipoprotein comprises a native coding sequence, or a part thereof, which is reintroduced into a Gram negative bacterium in a form which is different from the corresponding native polynucleotide. For example, the sequence
BE2017 / 5464 heterologous lipoprotein or polynucleotide gene may comprise a native coding sequence which is a part of a chimeric gene including non-native regulatory regions which is reintroduced into the native Gram negative bacteria.
However, the at least one lipoprotein of interest can also be a native lipoprotein which is an endogenously expressed lipoprotein and normally present in the cell. By way of nonlimiting example, the following are lipoproteins of particular interest:
fHbp (factor H binding protein)
The fHbp antigen has been characterized in detail. It is also known as the protein '741' (SEQ ID NO: 2535 and 2536 in reference 29), 'NMB 1870', 'GNA1870' [34 to 36], 'P2086', 'LP2086' or 'ORF2086' [ 37 to 39]. It is naturally a lipoprotein and it is expressed among many meningococcal serogroups. The structure of the C-terminal immunodominant domain of fHbp ('fHbpC') was determined by NMR [40]. This part of the protein forms an eight-stranded β-barrel, the strands of which are connected by loops of varying lengths. The barrel is preceded by a short helix and a flexible N-terminal tail. The protein was confirmed as a factor H binding protein, and named fHbp, in reference 41.
The fHbp antigen comes in three distinct variants [42] and it has been discovered that the serum directed against a given family is bactericidal within the same family, but is not active against
BE2017 / 5464 of the strains which express one of the two other families, that is to say that there is an intra-family cross protection, but no inter-family cross protection. The invention may use a single variant of fHbp, but to provide broader coverage a composition may usefully comprise at least two variants of fHbp or at least three variants of fHbp. The fHbp gene expresses a precursor protein that contains a lipoprotein signal motif, LXXC. The signal sequence is cleaved in such a way that cysteine (C) becomes the Nterminal end of mature fHbp and is modified cotraductionally to a tri-Pam-Cys residue which serves to anchor the protein to the outer neisserial membrane. Mature fHbp is 253 to 266 amino acids in length; most of the variation in size is the result of the variable length of a flexible segment or spacer, composed of 2 to 15 glycine and serine residues immediately following the N-terminal cysteine. Examples of sequences of the precursor protein and of mature fHbp are provided by SEQ ID NO: 8 and 9 respectively, other suitable sequences are known in the art.
NHBA (neisserial heparin-binding antigen) NHBA has been included in the published genomic sequence for the meningococcal strain B serogroup MC58 [30] as gene NMB2132 (accession number GenBank GL7227388; SEQ ID NO: 7 here). NHBA sequences from many strains have been published since then. For example, allelic forms of NHBA (called protein '287') can be
BE2017 / 5464 observed in Figures 5 and 15 of reference 33, and in Example 13 and in Figure 21 of reference 29 (SEQ ID NO: 3179 to 3184 in this reference). Many immunogenic fragments of NHBA have also been reported.
NadA (adhesin A neissérienne)
The 'NadA' (neisserial adhesin A) of serogroup B of N. meningitidis is disclosed as the protein '961' in reference 29 (SEQ ID NO: 2943 and 2944) and as 'NMB1994' in reference 30 (see also GenBank accession numbers: 11352904 and 7227256). A detailed description of the protein can be found in reference 31. When used according to the present invention, NadA can take various forms. Preferred forms of NadA include a C-terminal membrane anchor (e.g. residues 351 to 405 for strain 2996), since expression of NadA without its membrane anchor domain results in secretion of the protein into the culture supernatant. Particular NadA sequences have 50% or more identity (eg, 60%, 70%, 80%, 90%, 95%, 99% or more) with SEQ ID NO: 6. This includes variants of NadA (for example, allelic variants, homologs, orthologs, paralogs, mutants, etc.) Allelic forms of NadA are shown in Figure 9 of Reference 32.
Immunogenic compositions
Immunogenic compositions can include any suitable amount of membrane vesicles
BE2017 / 5464 external or GMMA per unit dose. Appropriate amounts of GMMA protein can be 0.1-200 µg per unit dose. Per unit dose, the immunogenic compositions of the invention may comprise a total concentration of GMMA protein
less than 200 pg / ml r lower than 100 pg / ml or lower, 80 pg / ml OR lower, 50 pg / ml or lower, 25 pg / ml OR lower, 20 pg / ml or lower, 15 pg / ml or lower, 10 pg / ml or
lower. Per unit dose, the compositions of the invention may comprise a total concentration of GMMA protein from 5 pg / ml to 200 pg / ml, from 5 pg / ml to 100 pg / ml, from 10 to 100 pg / ml, 10 pg / ml to 80 pg / ml, from 10 pg / ml to 50 pg / ml, 25 pg / ml to 50 pg / ml. Per unit dose, the immunogenic compositions of the invention may comprise a total concentration of GMMA protein of more than 100 pg / ml, more than 80 pg / ml, more than 50 pg / ml, more than 25 pg / ml, more 20 pg / ml, more than 15 pg / ml or more than 10 pg / ml.
The GMMA protein from each different serotype can be present in an amount of 0.1 to 200 pg, for example, 0.1 to 80 pg, 0.1 to 100 pg and in particular 5 to 25 pg. Appropriate amounts of GMMA from each different serotype may include 0.1, 1, 5, 10, 20, 25, 30, 35, 40, 45, 50,
60, 70, 80, 90 and 100 pg per unit dose.
In short, the immunogenic compositions of the invention can be administered in single or multiple doses. A single dose of the immunogenic compositions of the invention may be effective. Alternatively, a unit dose followed by a second dose
BE2017 / 5464 unit can be effective. Generally, the second (or third, fourth, fifth, etc.) unit dose is the same as the first unit dose. The second unit dose can be administered at any appropriate time after the first unit dose, especially after 1, 2 or 3 months. Generally, the immunogenic compositions of the invention will be administered intramuscularly, for example, by intramuscular administration into the thigh or upper arm as described below, but they may also be administered intradermally or intranasally.
The immunogenic compositions of the invention may include one or more adjuvants. Particular builders include aluminum builders, for example, aluminum hydroxide, Alhydrogel, aluminum phosphate, potassium aluminum sulfate and alum. The use of aluminum additives is advantageous since
The adsorption of GMMA on the adjuvant reduces the pyrogenic response allowing, in rabbits, to administer 100 times higher doses of GMMA compared to GMMA alone. The use of other adjuvants which also reduce the pyrogenic response is also envisaged and can be identified by a person skilled in the art using the tests illustrated below.
Pharmaceutical processes and uses
The immunogenic compositions of the invention may further comprise a pharmaceutically acceptable carrier. Typical "pharmaceutically acceptable carriers" include any
BE2017 / 5464 support which does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are generally large, slowly metabolized macromolecules such as proteins, polysaccharides, poly lactic acids, poly glycolic acids, polymeric amino acids, amino acid copolymers, sucrose, trehalose, lactose and lipid aggregates. (such as oil droplets or liposomes). Such supports are well known to a person with average skills in the field. The immunogenic compositions of the invention can also contain diluents, such as water, physiological saline, glycerol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like may be present. Physiological saline buffered by Tris, sterile pyrogen-free is a preferred support, particularly when aluminum adjuvants are used since the phosphate in the phosphate buffer solution can interfere with the binding of GMMA to aluminum.
The compositions can be prepared in the form of injectables, in the form of either liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared (e.g., a lyophilized composition or a freeze-dried spray composition). The composition can be prepared for topical administration, for example, in the form
BE2017 / 5464 of an ointment, a cream or a powder. The composition can be prepared for oral administration, for example, in the form of a tablet or capsule, in the form of a spray, or in the form of a syrup (optionally flavored). The composition can be prepared for pulmonary administration, for example, in the form of an inhaler, using a fine powder or a spray. The composition can be prepared in the form of a suppository or an ovum. The composition can be prepared for nasal, ear or eye administration, for example, in the form of drops. The composition can be in the form of a kit, designed such that a combined composition is reconstituted just before administration to a mammal. Such kits can include one or more antigens in liquid form and one or more freeze-dried antigens. The compositions can be presented in vials, or they can be presented in pre-filled syringes. Syringes can be supplied with or without a needle. A syringe will comprise a single dose of the composition, while a vial may comprise a single dose or multiple doses.
The aqueous compositions of the invention are also suitable for the reconstitution of other vaccines from a lyophilized form. When a composition of the invention is to be used for such an extemporaneous reconstitution, the invention provides a kit, which can comprise two vials, or can comprise a pre-filled syringe and a vial, with
BE2017 / 5464 the contents of the syringe being used to reactivate the contents of the vial before injection.
The compositions of the invention can be packaged in the form of a unit dose or in the form of multiple doses. For multiple dose forms, vials are preferred over pre-filled syringes. Effective dosage volumes can be established routinely, but a typical human dose of the composition has a volume of 0.5 ml, for example, for intramuscular injection.
The pH of the composition is preferably between 6 and 8, preferably around 7. A stable pH can be maintained by the use of a buffer. The immunogenic compositions of the invention can comprise a Tris buffer [Tris (hydroxymethyl) aminomethane]. The Tris buffer can include about 1 to 20 mM [Tris (hydroxymethyl) aminomethane], for example, 1.25 mM, 2.5 mM, 5.0 mM or 10.0 mM. The composition will be sterile. The compositions of the invention can be isotonic with respect to humans.
Thus, the compositions of the invention can be useful as vaccines. The vaccines according to the invention can be either prophylactic (that is to say, to prevent an infection) or therapeutic (that is to say, to treat an infection), but they will generally be prophylactic. The term "protected against infection" means that a subject's immune system has been sensitized (for example, by vaccination) to trigger an immune response and repel infection. It will be obvious to those skilled in the art that a vaccinated subject can thus
BE2017 / 5464 for example, combinations.
of the number, find themselves infected but is more likely to repel the infection than a control subject. The term "treatment" includes both therapeutic treatment and prophylactic or preventive treatment, in which the object is to prevent or lessen an infection. For example, treatment may include the action of directly touching or curing, suppressing, inhibiting, preventing, reducing the severity of, delaying the onset of, reducing symptoms associated with, infection, or any of their "Prevention" may relate to, inter alia, delaying the onset of symptoms, preventing a relapse into a disease, and the like. Treatment may also include "suppressing" or "inhibiting" an infection or disease, for example reducing the severity, incidence or latency of symptoms, improving symptoms, reduction of secondary symptoms, reduction of secondary infections, prolongation of patient survival, or combinations thereof. The immunogenic compositions used as vaccines include an immunologically effective amount of antigen (s), as well as any other component, as required. By "immunologically effective amount" it is meant that the administration of this amount to an individual, either as a single dose or as part of a series, is effective for treatment or prevention. This quantity varies according to the state of health and the physical condition of the individual to be treated, the age, the taxonomic group of the individual to be treated (by
BE2017 / 5464 example, non-human primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the assessment by the attending physician medical, and other relevant factors. The amount is expected to be in a relatively wide range which can be determined through routine testing.
The compositions of the invention may include an antimicrobial, particularly when packaged in a multiple dose format. The compositions of the invention may include sodium salts (e.g., sodium chloride) to give tone. A concentration of 10 ± 2 mg / ml NaCl is typical. In some embodiments, a concentration of 4 to 10 mg / ml NaCl can be used, for example, 9.0, 7.0, 6.75 or 4.5 mg / ml. The compositions of the invention will generally include a tampon.
Processing procedures
The invention also provides a method for raising an immune response in an appropriate mammal, comprising administering a pharmaceutical composition of the invention to the appropriate mammal. The immune response is preferably protective and preferably involves antibodies. The method may raise a callback response.
The suitable mammal can be an animal such as a cow, horse, dog, cat and the like, but is preferably a human. When the vaccine is intended for prophylactic use,
BE2017 / 5464 the human being can be a child (for example, a young child or an infant) or a teenager; when the vaccine is intended for therapeutic use, the human being can be an adult. A vaccine for children can also be given to adults, for example, to estimate safety, dosage, immunogenicity, etc. A preferred class of humans for treatment consists of women of reproductive age (for example, adolescent girls and above). Another favorite class is pregnant women.
The invention also provides a composition of the invention for use as a medicament. The medicament is preferably capable of raising an immune response in a mammal (i.e. it is an immunogenic composition) and is more preferably a vaccine. The invention also provides the use of a composition of the invention in the manufacture of a medicament for raising an immune response in a mammal. These uses and methods are preferably for the prevention and / or treatment of a disease and in particular, the immune response is a protective immune response.
The compositions of the invention will generally be administered directly to a patient. Direct administration can be accomplished by parenteral injection (e.g., subcutaneous, intraperitoneal, intravenous, intramuscular, or into the interstitial space of tissue), or by rectal, oral, vaginal administration
BE2017 / 5464 performed topical, transdermal, intranasal, ocular, auricular, pulmonary or other mucosal needle. Intramuscular administration in the thigh or upper arm is preferred. The injection may be using a needle (for example, a hypodermic), but a needle-less injection may be used alternatively. A typical intramuscular dose is 0.5 ml. The invention can be used to trigger systemic and / or mucosal immunity. Dosage treatment can be a single dose schedule or a multiple dose schedule. Multiple doses can be used in a primary immunization schedule and / or in a booster immunization schedule. A primary dose schedule may be followed by a booster dose schedule. The appropriate time between sensitization doses (for example, between 4 and 16 weeks), and between sensitization and the booster, can be routinely determined.
General
The term "comprising" includes "including" as well as "consisting of", for example, a composition "comprising" X may consist exclusively of X or it may include something additional, for example, X + Y.
The term "substantially" does not exclude "completely", for example, a composition which is "substantially free" of Y may be completely free of Y. Where necessary, the term "substantially" may be omitted from the definition of
The invention.
BE2017 / 5464
Unless otherwise specified, a process comprising a step of mixing two or more components does not require any specific order of mixing. Thus, the components can be mixed in any order. When there are three components then two components can be combined with each other, and then the combination can be combined with the third component, etc.
Unless otherwise indicated, the identity between polypeptide sequences is preferably determined by the SmithWaterman homology search algorithm as implemented in the MPSRCH program (Oxford Molecular), using a gap affine search with the parameters breach opening penalty = 12 and breach extension penalty = 1.
The practice of the present invention will employ, unless otherwise indicated, traditional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art. Such techniques are fully explained in the literature.
In certain implementations, the term “comprising” refers to the inclusion of the active agent indicated, such as the polypeptides mentioned, as well as to the inclusion of other active agents, and of supports, excipients, emollients , stabilizers, etc., pharmaceutically acceptable as known in the pharmaceutical industry. In certain implementations, the term “consisting essentially of” refers to a composition, the only active principle of which is the active principle or principles indicated, however, it
BE2017 / 5464 may be included other compounds which are intended for stabilization, preservation, etc. of the formulation, but which are not directly involved in the therapeutic effect of the active ingredient indicated. The use of the “essentially constituted” transition phase means that the scope of a claim is to be interpreted as encompassing the specified materials or steps cited in the claim, and those which do not materially affect the basic characteristic (s) and news of the claimed invention. See, In re Herz, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976) (in italics in the original); see also MPEP § 2111.03. Thus, the term "consisting essentially of" when used in a claim of this invention is not intended to be interpreted as being equivalent to "comprising". The term "consisting of" and its variations include including and limited to unless expressly specified otherwise. The term "approximately" in relation to a numerical value x means, for example, x + 10%, x + 5%, x + 4%, x + 3%, x + 2%, x + 1%.
Modes of Carrying Out the Invention
Example A
The outer membrane (OM) of Gram negative bacteria is an asymmetric lipid bilayer dotted with integral OM proteins and peripheral lipoproteins which are often immunogenic and can be exploited as vaccine antigens. The
BE2017 / 5464 lipoproteins (LP) are proteins characterized by the presence of a lipid cysteine which allows the anchoring of this molecule to the membrane (Kovacs-Simon, A., RW Titball, and SL Michell, Lipoproteins of bacterial pathogens. Infect Immun, 2011. 79 (2): p. 548-61).
Two of the main antigens of the Bexsero® multicomponent meningococcal group B vaccine are lipoproteins, namely the neisserial heparin-binding antigen (NHBA) and the factor H-binding protein (fHbp). In Neisseria meningitidis, as well as in other Gram negative bacteria, the lipoproteins intended for OM are synthesized in the form of a precursor in the cytosol and subjected to translocation through the internal membrane (IM) by dry machinery. and then to the outer membrane (OM) through the Loi system. The Loi system transports them through the periplasm and secures the proteins to OM by incorporating the diacylglycerol fraction into the internal leaf of OM (Bos, MP, V. Robert, and J. Tommassen, Biogenesis of the gram- negative bacterial outer membrane. Annu Rev Microbiol, 2007. 61: p. 191214).
The specific component of translocation, SLAM1 (modulating flippases 1 for the assembly of lipoproteins at the surface), involved in the surface exposure of lipoproteins specific for N. meningitidis, has recently been identified as being sufficient to reconstitute transport of certain meningococcal lipoproteins to the surface of E. coli (fHbp, TbpB and LpbB) (Yogesh Hooda, C.C.-L.L
BE2017 / 5464
Andrew Judd, Carolyn M. Buckwalter, Hyejin Esther Shin, Scott D. Gray-Owen and Trevor F. Moraes, Slam is an outer membrane protein that is required for the surface display of lipidated virulence factors in Neisseria. Nature microbiology, 2016. 1).
SLAM1 is encoded by the nmb0313 gene and is an outer membrane protein characterized by the presence of an N-terminal domain with a tetratricopeptide repeat domain (TPR) and a structured C-terminal transmembrane domain as a porine type domain (Figure 1 (A)).
In order to better characterize the functionality of this protein, the nmb0313 gene was deleted in different representative strains of N. meningitidis from group B, MC58, NGH38 and NZ 98/254 (Figure 1 (B)). Inactivation (knockout) was obtained by replacing the nmb0313 gene with an antibiotic resistance cassette as follows, results confirmed by a Western blot analysis (Figure 2).
Bacterial strains and culture conditions
The Neisseria meningitidis (Nm) strains from serogroup B (MC58, NHGH38, NZ 98/254 and its isogenic derivatives) and the Escherichia coli (Ec) strains (DH5a and BL21-DE3) used in this study are listed in the table 1 below:
Last name Description Cassette ofresistance toantibiotic
BE2017 / 5464
Last name Description Cassette ofresistance toantibiotic MC5 8 Adapted reference strainsat the Neisseria laboratorymeningitidis NGH38 Neisseria meningitidis NZ 98/254 Neisseria meningitidis MC5 8Δ0313 Neisseria derivativemeningitidis MC58, insertionkanamycin in the locusfrom nmb 0 313 kanamycin NGH38Δ0313 Neisseria derivativemeningitidis NGH38,insertion of kanamycin inthe locus of nmb0313 kanamycin ΝΖΔ0313 Neisseria derivativemeningitidis NZ 98/254,kanamycin insertionin the locus of nmb0313 kanamycin
BE2017 / 5464
Last name Description Cassette ofresistance toantibiotic MC58A0313 Neisseria derivative Chloramphenicol CÏ0313 meningitidis MC58, to which itmissing the nmb0313 gene witha copy of nmb0313reintroduced outside oflocus under the control of ainducible PTAC promoterby IPTG NGH38 Neisseria derivative Chloramphenicol Δ0313 meningitidis NGH38, to which CÏ0313 the nmb0313 gene is missingwith a copy of nmb0313reintroduced outside oflocus under the control of ainducible PTAC promoterby IPTG DH5a E. coli: fhuA2 lac (del) U169phoA glnV44 Φ80 'lacZ (del) MIS gyrA96 recAlrelAl endAl thi-1 hsdR17 BL21(DE3) E. coli: BL21 E. coli: BL21 (DE3) to which (DE3)ATolR the b0738 gene is missing
BE2017 / 5464
The N. meningitidis strains were cultured on agar plates of gonococcal base medium (GC) (Difco) or in GC broth at 37 ° C in 5% CO2. The strains of E. coli were grown in LB agar or LB broth at 37 ° C.
Antibiotics were added when necessary. Kanamycin and chloramphenicol were added at final concentrations of 150 pg / ml and 5 pg / ml for the selection of deletion mutants and complementing strains of N. meningitidis, respectively. Ampicillin, kanamycin, or
chloramphenicol has been added to of concentrations finals of 100, 150 or 10 pg / ml for the selection of EL coli. When necessary, from 1' 'isopropyl-ß-D- 1-thiogalactopyranoside (IPTG) (1 mM) (Sigma) was added to the backgrounds of culture to the concentrations final indicated.
Construction of mutant and complementation strains
The DNA manipulations were carried out using conventional laboratory methods (Sambrook J, F.E., Maniatis T, Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, 1989. 2nd ed.)
To construct the mutant by deletion of NMB0313, the nmb0313 gene was replaced by a kanamycin cassette by double crossing over. To achieve this, the plasmid pGEMTUD313Kan was produced as follows. The
BE2017 / 5464 flanking regions upstream and downstream of nmb0313 were amplified from the chromosome of MC58 with restriction enzyme sites and cloned into the plasmid pGEMT. The kanamycin cassette was cloned as a 1.4 kb Xbal fragment in the Xbal site between the two flanking regions. This plasmid was used to transform strains of N. meningitidis.
The complementation of nmb0313 was obtained by inserting a copy of nmb0313 in the non-coding region between the convergent ORFs NMB1428 and NMB1429 of the chromosome of the Δ0313 strains. To achieve this, the plasmid pComPIndNMB0313 was produced by amplifying the nmb0313 gene and cloned in the form of an Asel / Nsil fragment under the control of the inducible promoter Tac and the Lacl repressor in the plasmid pComPInd (leva, R., etah, CrgA is an inducible LysR-type regulator of Neisseria meningitidis, acting both as a repressor and as an activator of gene transcription. J Bacterid, 2005. 187 (10): p. 3421-30). The primers and plasmids are listed in Tables 2 and 3 below:
BE2017 / 5464
Table 2
Last name Description Cassette ofresistance toantibiotic Reference pCOLA DUET The vector code fortwo cloning sitesmultiple with theT7 promoter, theCOLA replicon fromfrom ColA, the repressorlacl and KanR Kanamycin Novagen pGEM-T Cloning vectorof. coli, AmpR Ampicillin Promega pComP _IND CmR Plasmid for theallelic replacementat alocationchromosomal betweenORF NMB1428 and NMB1429and expressioninducible under thepromoter controlPTAC and repressorlacl. Upstream of the sitecloning there is aresistance cassetteat cm Ampicillin,Chloramphenicol leva, R.,et al. JBacteriol,2005. pUD0313Kan pGEM-T containing theflanking region ofnmb0313 with theresistance cassetteto Kan cloned asXmal fragment betweenflanking regions Ampicillin,Kanamycin Thisstudy
BE2017 / 5464
Last name Description Cassette ofresistance toantibiotic Reference PIND ΝΗΒΑ-f Hbp(fusionPIND N-f) Plasmid forcomplementation of thefusion proteinNHBA-fHbp withthe N-terminal endNHBA and the domainC-terminal in theCorn region with aTac promoterinducible by IPTG. Ampicillin,Chloramphenicol Thisstudy pIND0313 Plasmid forcomplementation ofnmb0313 in the regionCorn with a promoterinducible tac bythe IPTG. Downstream ofnmb0313, is cloned oneresistance cassetteat Cm. Ampicillin,Chloramphenicol Thisstudy pCOLA_0313 Construction forexpress proteinNMB0313 recombinant fromN. meningitidis inE. coli Kanamycin Thisstudy pIND NHBA Construction forexpress the protein p3of the NHBA variant ofN. meningitidis MC58in E. coli Ampicillin,Chloramphenicol Thisstudy
BE2017 / 5464
Last name Description Cassette ofresistance toantibiotic Reference pIND fHbp Construction for Ampicillin, This express proteinvl.1 of the variant of theN. meningitidis fHbpMC58 in E. coli Chloramphenicol study GeneArt Constructionwith an N- domainNHBA terminalmerged into domain C-fHbp terminal Ampicillin Thisstudy
Table 3
Name ofThe primer Application Sequence 0313UP_F Fragment for theproduction of 0313 KOin MenB GAGATCTAGAGCCGGCATTCGGGCAAAAACC 0313UP_R Start of merger upstreamand downstream of the flank ofNMB0313 with a site ofXmal restriction AACAGCAACCCGGGTATCAATCGGCGGAT NMB0313 FW DO Start of merger upstreamand downstream of the flank ofNMB0313 with a site ofXmal restriction CCGATTGATACCCGGGTTGCTGTTCCTTTTCG 0313pC_F Cloning of the NMB0313 genein the plasmid pCOMfor complementationin MENB NM0313KO GTGTATTAATATGGTTATTTTTTATTTTTGTG
BE2017 / 5464
0313pC_R Cloning of NMB0313 inthe plasmid pCOM for thecomplementation in MENESNM0313KO GTGTATGCATTCAGAACGTTTTATTAAACTC 0313pD F2 Cloning of the NMES0313 genein MCS2 from pCOLA GTGTATTAATATGGTTATTTTTTATTTTTGTG 0313pD R2 Cloning of the NMES0313 genein MCS2 from pCOLA GTGTCTCGAGTCAGAACGTTTTATTAAACTC
The correct nucleotide sequence of each plasmid was confirmed by DNA sequencing. The plasmids were linearized and used for the transformation of the strains of N. meningitidis. All transformants were checked by both PCR and Western blot analysis as follows:
Western blot analysis
Strains grown for a night sure of agar plates have been put back in suspension in of GC broth until a DOsoo of 0.5. 1 ml of the resuspension at summer centrifugal while 5 min at 13,000 rpm and the pellet was refitted suspension
in 50 μΐ of SDS loading buffer (50 mM TrisHC1 [H 6.8], 2.5% SDS, 0.1% bromophenol blue, 10% glycerol, 5% 3-mercaptoethanol, 50 mM de DTT) (Oriente, F., V. Scarlato, and I. Delany, Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNRregulated promoter. J Bacteriol, 2010. 192 (3): p. 691701) .
Liquid cultures were grown until an OD600 of 0.50 was reached and 1 ml of the
BE2017 / 5464 culture was aggregated and resuspended in 50 μΐ of SDS loading buffer. The protein extracts were separated by SDS-PAGE on NuPAGE® Novex® 4-12% Bis-Tris Protein Gels gels in MES IX (Life Technologies) and then transferred to nitrocellulose membranes. The membranes were blocked overnight at 4 ° C with PBS + 0.05% Tween 20 (Sigma) and 10% milk powder (Sigma). The primary antibody was diluted (Table 4) in
PBS + 0.05% Tween 20 and 3% milk powder and incubated for 1 hour with the membrane.
Antibody table DilutionWB DilutionFACS Serumα-fHbp polyclonal of mouse 1/5000 1/1000 Serum polyclonal of mouse 1/2000 1/1000 a-NHBA Serum monoclonal of mouse 1/1000 a-NHBA a-mouse-FITC 1/1000 a-mouse-HRP 1/1000
Anti-mouse IgG antibody conjugated to horseradish peroxidase (HRP) and the Western Lightning ECL reagent (Perkin Elmer) were used according to the
BE2017 / 5464 manufacturer's instructions for detection. The results are shown in Figure 2.
After the production of nmbO313RQ, the mutants were analyzed for the presence on the surface of lipoproteins exposed on the surface known as NHBA and fHbp:
Fluorescence Activated Cell (FACS) Sorting Analysis of fHbp / NHBA Expression
Strains of N. meningitidis and isogenic derivatives were collected after liquid cultures at DCPoo 0.5, when necessary, IPTG was also added. The bacteria were inactivated by incubation with 0.5% formaldehyde for 1 hour at room temperature. The labeling was carried out with the primary antibody diluted in BSA (Sigma) as reported in The binding of the primary antibody was using an anti-mouse antibody (whole molecule) conjugated to FITC (Sigma) at the correct dilution (Figure 3).
The deletion of nmb0313 affects the surface exposure of the lipoproteins analyzed in the chosen meningococcal strains. In particular, the absence of NMB0313 leads to a lack of detectable levels of NHBA on the cell surface with the simultaneous accumulation of NHBA within bacteria. In contrast, decreased levels of fHbp were detected on the cell surface and these low levels were a
PBS-0.5% Table 4 detected as a consequence of a general reduction in the amount of fHbp in the context of nmb0313 KO compared to the wild type. Therefore, NMB0313 plays a role
BE2017 / 5464 essential in the translocation of NHBA on the surface of the bacteria but its deletion does not affect the expression of NHBA in itself. However, NMB0313 contributes to the stable expression of fHbp and therefore to its expression at the surface.
Then, the phenotype was restored in the NGH38 nmb0313 KO strain by genomic complementation of a functional copy of the nmb0313 gene under the control of the Tac promoter inducible by IPTG (FIG. 4A). The complemented strain is capable of expressing NMB0313 in a manner dependent on IPTG as shown by Western blot analysis and the highest concentrations of IPTG induce an overexpression of the protein NMB0313 compared to the levels of type. wild (Figure 4B).
The complemented strain was then analyzed for surface exposure of NHBA and fHbp (Figure 5). Expression on the surface of NHBA and fHbp was restored in the strain supplemented with nmb0313. Interestingly, the increased expression levels of NMB0313 resulted in a simultaneous increase in surface expression of both NHBA and fHbp as observed by FACS analyzes and surprisingly, overexpression of NMB0313, at a concentration of 0.1 and 1 mM IPTG, resulted in higher surface area levels of NHBA and fHbp compared to the wild type strain. From Western blot analysis, this appears to be due to increased expression levels of these lipoproteins in the overexpressing strain NMB0313.
BE2017 / 5464
Coexpression of flippase with lipoproteins in a heterologous system
The fHbp and NHBA lipoproteins derived from N. meningitidis MC58 were cloned under the control of a promoter inducible by IPTG and expressed in a non-pathogenic strain of Escherichia coli alone or with coexpression of NMB0313. The strain of E. coli BL21 (DE3) was cotransformed with two different comparable plasmids carrying fHbp or NHBA and nmb0313, respectively or as a negative control a plasmid carrying fHBP or NHBA and the empty plasmid pCOLA. The expression levels of the two proteins responded to IPTG induction and the expression of the two proteins was confirmed by WB analysis (Figure 6).
In the presence of NMB0313, the amount of fHbp in the total extracts greatly increased compared to the strain expressing fHbp alone. This increased level of fHbp was reflected by higher detectable fHbp on the surface of E. coli.
The expression of fHbp alone is detectable both in Western Blot analysis and by FACS on the surface of E. coli only at concentrations of 0.01 and 0.1 mM IPTG, however, during the simultaneous coexpression of NMB0313, expression is also detectable at concentrations of 0.001 mM IPTG and at higher levels of IPTG, the coexpression of NMB0313 results in significantly more expression of fHBP overall and on the surface of E. coli. These results indicate that NMB0313 has a positive effect on
BE2017 / 5464
Detectable analysis stable expression and expression at the surface of fHBP in E. coli.
Preliminary results of NHBA expression in strains of E. coli demonstrate the stable expression of NHBA in the samples both in the presence or in the absence of NMB0313, while FACS reveals that there is no NHBA on the cell surface of E. coli.
However, when NHBA is expressed with NMB0313, bacteria also show NHBA on the surface, confirming the key role of NMB0313 in translocating NHBA across the surface.
Production of OMV from strains expressing flippases
The complemented NGH38 strain described above is used to produce outer membrane vesicles. In short, to abolish the production of the capsule, a fragment of the bacterial chromosome containing synX, ctrA and the promoter controlling their expression, is replaced by a gene for resistance to spectinomycin. First, the recombination sites are amplified from genomic DNA with the following primers:
ctrAf_Xma: CCCCCCGGGCAGGAAAGCGCTGCATAG;
[SEQ ID NO: 10] ctrAr_Xba: CGTCTAGAGGTTCAACGGCAAATGTGC;
[SEQ ID NO: 11]
Synf_Kpn: CGGGGTACCCGTGGAATGTTTCTGCTCAA;
[SEQ ID NO: 12]
Synr_Spe: GGACTAGTCCATTAGGCCTAAATGCCTG;
[SEQ ID NO: 13]
BE2017 / 5464
The fragments are pComPtac (leva et al., Inserted in J Bacteriol, pp. 3421-3430) upstream and the plasmid 187 (2005), of the gene of the downstream gene Then, resistance to chloramphenicol resistance to chloramphenicol is replaced by a spectinomycin resistance cassette. The IpxLl gene is deleted by replacement with a kanamycin resistance gene (Koeberling et al., J Infect Dis, 198 (2008), pp. 262-270) and the gna33 gene with an erythromycin resistance cassette (Adu -Bobie et al., Infect Immun, 72 (2004), pp. 1914-1919).
GMMA preparation
The bacteria are cultured at 37 ° C., 5% CO 2 in 50 ml of a medium defined for meningococci at 180 rpm until the early stationary phase. The cells were harvested (2200 g, 30 min, 4 ° C.) and the culture supernatant containing the GMMAs is filtered through a membrane with a pore size of 0.22 μm (Millipore, Billerica, MA, States -United)
To collect ultracentrifuged
GMMA, the supernatant is (142,000 x g, 2h, 4 ° C). The membrane pellet is washed with phosphate buffer solution (PBS), resuspended in PBS and sterilized by filtration. The concentration of GMMAs is measured according to the protein content by the Lowry test (Sigma-Aldrich, St. Louis, MO, United States). For the analysis of proteins and lipooligosaccharide, the GMMAs are separated by SDSPAGE using a 12% gel and MOPS or MES buffer (Invitrogen, Carlsbad, CA, United States). Total proteins are stained with Coomassie blue staining. FHbp is detected by Western
BE2017 / 5464 blot using a polyclonal antibody as described above.
Mouse immunization
Female CD-I mice are obtained from Charles River Laboratories (Wilmington, MA, USA). Eight mice per group are immunized intraperitoneally three times with 2 week intervals. Serum samples are obtained 2 weeks after the third dose. OMVs from the overexpressing strain are given at doses of 0.2, 1 and 5 µg based on total protein. Control mice are immunized with only 5 µg of aluminum hydroxide. All the vaccines are adsorbed on 3 mg / ml of aluminum hydroxide in a 100 μΐ formulation containing 10 mM of histidine and 0.9 mg / ml of NaCl. The sera will be stored at -80 ° C until use. All work on animals has been approved by the Italian Animal Ethics Committee.
Serological analysis
The anti-fHbp IgG antibody titers are measured by an ELISA test as described in Beernink et al. (Clin Vaccine Immunol, 17 (2010), pp. 1074-1078).
While certain embodiments of the invention or the invention are limited to such embodiments, various modifications may be made thereto without departing from the scope and spirit of the present invention as presented in the the present invention claims have specifically above, described and illustrated is not intended that the following
BE2017 / 5464
Sequences
SEQ ID NO: 1; gi177358697: 323429-324895 Neisseria meningitidis MC58
ATœTTATmTTATTTTÎGTGGGAÂOACATTTATG € CT € <ACGA.AACAGATGGATG € TG
CTCjGTGG <'TTTATTGGGAAGC'CCOCKATATGC' € CiAAGAAA <'A <' CCK CK GAAGCGGATTT
GAGAAŒCGTCCCCAGTTCAGÂTTCATGÂAGCGGAGOTCAAACCGATCGACAGGGAG
AAGGTGCGGCX AjGAG <3TGCGGGAAAAAGGAAAAOTTTTG <'AGATTGACGG <' GAAAGCG
T € A'TGAAAAATCCGGAATT <3TTGT (7c: 'CCX CX GATGTATTCGG <7AGTGCiTCTGAAA <' AAT
ATKX7 <'GGTATCÎ7 <X7GTTATTTTœC'GATTTAÎ7CTACAAÎ7ACX7A'CC'AGt'A <XïATAAGAT
GTTGGC ACrrrATGCAQVWGG, 'VrnTGG £ OC AGGC'AGATGGIAGGGTGAAGGAGGCG
ArriCCOÂTrA <X CKXîAATrGArr <X: < (X ŒÂA < CS: 'GACGCŒT <' <K'CGTCC'CÏAiœGT
TTG <XX7X X7A £ X7A'r Grr <IAAAA < A < XX AGAA <X7AG € <XXX'G <X'A'GACi7AG'BX''GACC
GCi / TGAAG <XX7X UVxAA <X7TGi / CCXXTX A <jC OA7 <XsACX'AGG CGAGC'TGl'A <X''GCAA
G ^ ATTGC'GtOAArGCGATGCGTGGÄAGGrAÄATGGCGGCTTCACXOK'ACCCGCGAA rACAATATCÄACCAAGCCCCGÄAACGGCAGCAGTACGGCAAATGGACTn'CCCGA.AAC
ÄGGTGGACGGC'ACGGCGGTCÄATTACCGGC'TCGGC’GCGGAGAAAAAATGGTCGCTGAA
A WGCA'TCA5TACACGACOGCGGGCGG <OA € 'GTGr <X FXX'AGCXJTnATCi7GGGGAAT
AA <sAAAÏXX7AA <X IATArGA (7G <X'A <XXXymX F7G <XXXX7AlX7G <ïïrnXXX GAi7 <XXX7G <'AAAGATCX' € (X XiCTG <X'AGTGTT € C ACGAAC GCCCXAi / CTACGCT AATTGA.A
CriÂCACf AACG <if G € A ( GCf ΊΊ'ΓΑΓΓΚ'ΑΑα / σΓΓΟίΧ'ΛΑΑΑυί'ί'Ο AAAÏGfX'AAAGG n <yr < TKXKX (XjAGraXXXX '<nTTGA, AGAATAC <XXX'C <XXKTK {YrrCCGiXCA ArAC € ί7ΧΓΓΤΰ € ΑΑΑΤΓΚ '<7ΑΑΤΓί / <Χ7ΊΧΧϊΚ ΪΓΓΓΤΑ € ί7 < <Ϊ́ΑΑΊΧΧΧΧΧ ΧΧ ΑΑΤΑΤΠΧ Ϊ́ΑΊΧΧ ! <Ϊ́
CGGTTTGGATTTTTACCŒ'GAGCGC'AACCX'CGCÎOACCCKXjGCGACAATTÎCAACCGTT .ACôŒ'CTCCCC'TTTGCCTGGGGŒAGGAATGGGGCGŒAGCCîGC'CTGTrTrCGC'TGTTG
CXX'CTCGXXXXXXX GAAA <XXXA'rTAIGAAAAA <X <XXX7rrn'ÏI'A <XXXjrrnAAACîG œAAALKX'Œ'AÇjœÂTAAAGAATTGAAL'AGATCCITGAiiCGTTTŒiCACCCjGGÎ'.ÂTTCK
ATTTCAAAGGCATCA <'OCrGCGCCTGACGTTGKGCAC <O € -GAAACGCGGAGTAACGAT
GTGTTCAACGAATACGAGA, AAA.AKOGGCGTTTGKGAOTTTAÄTAA, AACGTrCTGÄ
SEQ ID NO: 2; Q9K165 | Y0313_NEIMB protein NMB0313 containing TPR repeats
BE2017 / 5464
MVffYFCOKimR / ARNSWMIJJ..R1J.ASAAYARETPRFPDLRSRPRFRl.HEAEVKPiDREK.V
<iQVRFRGS R..Q1DY: jEïï.l.KNRELj.ARAYÎYSAVVSNNÏA < ÎRV1E.PÎYI.QQAQQDRM1, AFYA <X »ÎLAQAlX5RVŒAÎSÎiYR £ LIAÀQ DA ÂQQLALAAA
FQLMEQV ^ YSKAIJŒRDAW ^ WœFSXniŒïîhTNQAPKRQQYGKWTn ^ OXTXjïAVNY
KLô / lEKKWSLKNOW ^ nTAœDVSŒV ^ TGh ^ KFNDNlTAôVSÔGieFADRRKDAôLAVFH
PRRTYGNDAYSYI 'GAKiYFN'RWQ'FPKVVQ'rLSRAEWCPLKN'ÏRRARSDNTFR, QiSN $ LVF
YRNARQYWMGOLDF ¥ RERNPADRGDNENRYGL8F WöQEWöGSöi.RSLLRLGAAKSHY
ERPGFESGFKGERRRDREEXTSLS1AlE-iRALHEKG1TPRl.II-SHRE.TRSND ENETTKXRÂR '
EENRTE
SEQ ID NO: 3; tr | Q9JXM5 | Q9JXM5_NEIMB uncharacterized protein
MLYFRYGFL ^^ T.AAGVSAÂYC »» ADAPAELDDKALLQVQRSVSDKWA £ SDXVKVENDAî ^ t
YATXJDFEEAHPKMEEHSERDAENGNQADnASLADLYAREPDYDAYT.YGRARALEARLAG
RPAEAVARYRELHGENAADEEILLDLAAAEEDDERE & SAERHEAEAAXLDLPAPVEENVGR
FRKKIEGLTG ^Tf RESCR1JSPA ⁱ KRXANNAÄ <^ JYTP.QXGGRQR'SYSPAEPXAGLNYEIEAEK The rPLADMnTE11iSNTCV3ISYYTS SAYDDi3FGRAYLGWYKN, RQTAOiLPFYQYQLSÖ SJXfFDAKTKRVNNRRLRRY ^ Y ^ iLÂîîGVOVQLSFîrYRPNPGWQESVALEFIYRQRYREQDRAS ÖRQDGFSVSSAKSLGESAIVTGGXVQFWFVPKRETVGGä'VNNAäYSRNGX YAGWA ^ ^ ^^ Ε Ε € <τΕΑ Υ ^ ^ ^ Α9ΥΑΡ ΝΎΚΟ1ΑΑΕ5ΤΕΑΡΕΝΕΕ ^Υ ί ^! ν5ΕΑΕ $ ΗΕ) ΚΕΑΥΚ € τΑ · ^ί ΡΑΕΝΥ 'RFGRrESNVPYARRRNSFYPVSADWRE
SEQ ID NO: 4; tr | Α0Α0Y0BKC0 | Α0Α0Y0BKC0_STREE protein NMB0313 containing TPR repeats; Streptococcus pneumoniae ^ A¾ÏQÏKFHJTS $ SLfLTPYSVΛYERSPQPP2DöEWEQL ^ SukRPNLPQKRÏί LLΊ / ^ R <NFSKLSI 'iYE.ELÄKPiPDLERGLIPAVFQNNöPAYQI..LLPLYQPPL
VKAYRHLÏ ^ QKTOLLPLRYQLAQÂLFLNWNEilAKIXJFQKLRAEQVSPDSYKHEQYLSAL
YQEJ> QWKKj <XïPSFLNP.SNÏNNAPKAGTE1GNW A VPXFSARGPSYPGN.AEKi <WSFRHNH
FTRlALEGSGSYAAVGNRRYNEPNARAGAGFGYQTARFEW.MRPTESRUG ^ GCsSSGFiNA
MK.QYSKNSGARF.DLSAAVÏ.NEKWQISTALE.YGEQRYEFRRHÎ, NYiNNYÎ, ASATFI, YLAKSGQ
Yd.VFCîGADY'NRENTRDLDNAY ^r QRKN REGYVGQE ^ ^! KAGÎSTRLE .. 'Y'ARRAY ^, KEKDIJGIRQ
RNREYASVFTR TÎRNFHIWGn'PKI, SWSYÇ1RVTSNHPfY''EYl> RNÎlïY YEÎSKTE
SEQ ID NO: 5: R2846 1315
BE2017 / 5464
MK ^ ^r GVKQLSLL · SΠGL5L'FNVAWAEVARPKNDTLlNΊlQSÄELK'I'SSFSSMPKKEI ^^ H nSIAK.SQL ^ HHPRIA <LRGLFPALYQNN7QAVQLLLFLYKQFPQQDNELLÏWAS.AÏEARE
QöDLTQSLY ^ RELFAPNASLLPLRYQLAQALEFNY'ENEAeAKIQFEKLR.TEV ^ DDEKFLöV
ÎDQYLLTLXQEA ^Î QY _Î ^Î 1AVQVGLNEÎAWNLN 'AFKSÔTKÎGS VTA \ ŒKE.SGQGYGY'SLSVEK
KWFWAGiiEESKlWERENYIKYYWDNKKYXE / A'rYRlGGGEGYQTASVEVSLEFEQEKRWYA
G GSSGIN ^ îKQYÂDSWîRXI ^ VDÂVLSKTWQlSIAI ^ YGESKYKIRKiaiXiNYYnSSIXr
YLPK.STQB3 ^ V <WA ^ ÎRENrQÂn> L6 Y <^ RT.IJ <LGWeÇ> »WSHGISSRLTFSYÆ 'RWREK
DUGX <XjKNREYTXTrîLWîlRNaiFMGLT KLSWDYQKSISXiiAFYRYDKNïUYlJîïGKIF
SEQ ID NO: 6: NadA
ÂTNDDDY'KKAÂTVGViÂAAYNNGQEINGFFDlGETIYOIDEDGTn'RKDÂYAADXŒADDFKGL
6ΕΧΚνΥΤΝΕΉ <ΤΥ ^ΐ ΈΝ ^ ΝΛΊ> ΑΚΥΈΧΑΕ8ΕΪΕΚΕΪΤΚΕ <4Ι>ΤΟΑΑύΥ0'Ο> ΑΑΕΟΑΤΕΧΑΕΧ
ΚΙ, ΟΕ ^ · ΓπΐΑΕΕΙΚ'ΪΧηΤ <Π> ΕΚΙ.ΕΑΥΛΠΤνΓ) ΚΚΑΕΑΪ>; ΐ> ίΛΐ) 8Ι.0ΕΤΝ · Γ & ΑΪ) ΕΑνΚΊ'ΑΗΕΑ
KQT ^ AEETKQKVDAKYKAAETAAGKAfAÆAGTANTÆADKAEAVAAKVWÎKADÎATNRDN
LAKRANYADY'Y'TREESDSKFVTîIDGiXATTEKLDTSJASAEKSIADHDTRLNGLDKTYSDLR
KETRQGLAEQAALSGtEQFYNVG
SEQ ID NO: 7; gi | 7227388 | gb | AAF42440.1 | protein related to the transferrin binding protein [Neisseria meningitidis MC58]
KÖ-lOlSYXAMACJFALSÄCG ^ üCSGSPDVKSAm'LSKPAAPVVSEKE’rEAKEDAPQAGSQGQ
G PSA <Xï $ QDMA / YSEENTGNG <LWTADN KNTGEVAQNDMFQNAAGTDSS'FPNTiTPD
NA ^ o ^ MEM; jArDAGESSQF _; ^ NQ D ^ NAArX1MQGLn> ^ CXÏQNAGNnAÂ <KïANQAG
Ν ^ Α.ΥΌΥ ^ ΠΡΪΡΑΥΝΡΑΡΑΝΕτΟΧΝΕΌΚ ^ Ε.ΑΝΟΥΤΙΪΧΙΡ ^ ΟΝίΤΕΙΙΧΚΟΕ ^^ ΑΌΝΝΕΕΒΕΕ
VQXiDÎEEEKXAFMDKÎSNYKKXXfKNDKFVGLVADSVQMKGn> iQ lïFY'K KPTSEASPÏîRSA
RSRRSLPAEXYPEIPYNQADTRIVIXrEAVSLTGHSGNIFAPEGNYRYEEYGAEKIiY / XiSYALP.
VÇCïERAX <GEMIAGAAVYYGEVLHFKIENGRFY TRGRFAAKY7> EG $ K $ TX7nrJYGrJDLH
MGTQREK. ^ NXÏNGFRGTYTEN'GRGDYtSGKEYGPAGEEVAijKYSYRPTDAEKGGFGVFA
GKKEQD
SEQ ID NO: 8
ΜΡΕΕΡΡΕσΡΗΕ.ΙΕΑ5ΐ / Γ € Ι1ΟΑν <7ΚΚΧΥ.ΗΝ! 0ΝνΥίί.8ΙΪΧΜΤΡ8ΚΡνΝΕ.ΤΑΕ <'< ΙΑΪ, ΤΓΑΕΪί, Τ
AÎ’SSœœVAADiGAGIJŒlALTAFWiSiDKôî ^ SLTLDQSVRKNEKLKiJSkÂQGAEKTYON
GDSLKTGKLKNX> KVSRÎDFÎRQIEVIXXQLÎTLESGEFQV 'KQSHSALTAFQTEQXQDSEHSGK
MVAKRQFXUGDIÄGEHIBFDKLPEGGXtAXYRGrAPGSDDA15GKLlVnDEÄAKQÖNGKXEH
LXSFEL.NVI) l.AAAGÏKPÏXjKKHAVÏS <ESVE.YNQÂEK <; SYSEGR'GGKAQEVAGSA.PVKrVN
ŒRHKH.ÂAXQ
BE2017 / 5464
SEQ ID NO: 9
CSSGöÖöSGCKK »VÄADIOAOLÄDÄLTÄPLi» S3> KöLKSLTLEDSiSQNOTLTLSAQöAER.T
FKÂOÏ> KDKS {.KTGKLKXOK5SRH> r4RQÎE nX "QLJTÏ.ES" BPQIYKQ "HSA ’ V / F..Q1EKn <S ^
DKÎD5LÎNQASFRVSGLGGENT, 4ID <QLPIiG-KAEyNGK, toFSSDDACtoKLT9NIDF3ARQGNG
ΚΙ.Ε6ΙΠ <ΤΡΕςΕ ΑΈΕΑ9Α ££ Κ, ύΟΕΚ9ΗΑνίΕ6ϋΤΕ ¥ Ο9ΕΕΧ0ΤΥΗΕΑΕΕθηΕΑ0ΕΕύ € ΑΑΡ2Κ
ÏGEKWEIGÏAGKQ
BE2017 / 5464
References
2. S.F Sanzone, O production
1. A. Kulp, M.J. Kuehn Biological functions and biogenesis of secreted bacterial outer membrane vesicles Annual Review of Microbiology, 64 (2010), pp. 163-184
Berlanda, A.M. Colucci, L. Maggiore, S. Rossi, I. Ferlenghi, et al. High yield process for Shigella outer membrane particles, PLoS One, 7 (2012), p. e35616.
1. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2197-2223.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2095-2128.
3. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2013; 382: 209-222.
4. Livio S, Strockbine NA, Panchalingam S, Tennant SM, Barry EM, Marohn ME, et al. Shigella isolates from the global enteric multicenter study inform vaccine development. Clin Infect Dis. 2014; 59: 933-941.
5. Levine MM, Kotloff KL, Barry EM, Pasetti MF,
Sztein MB. Clinical trials of Shigella vaccines: two
BE2017 / 5464 steps forward and one step back on a long, hard road. Nat Rev Microbiol. 2007; 5: 540-553.
6. Chang Z, Lu S, Chen L, Jin Q, Yang J. Causative species and serotypes of shigellosis in mainland China: systematic review and meta-analysis. PLoS One. 2012; 7: e52515.
7. Vinh H, Nhu NTK, Nga TVT, Duy PT, Campbell JI, Hoang NVM, et al. A changing picture of shigellosis in southern Vietnam: shifting species dominance, antimicrobial susceptibility and clinical presentation. BMC Infect Dis. 2009; 9: 204.
8. Kweon, 2008 Curr Opin Infect Dis. 21 (3): 313-8.
9. Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, et al. Double-blind vaccinecontrolled randomized efficacy trial of an investigational Shigella sonner conjugate vaccine in young adults. Lancet. 1997; 349: 155-159.
10. Passwell JH, Ashkenzi S, Banet-Levi Y, RamonSaraf R, Farzam N, Lerner-Geva L, et al. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccinated. 2010; 28: 2231-2235.
11. Susanna Esposito, Roman Prymula, Gian Vincenzo Zuccotti, Fang Xie, Michelangelo Barone, Peter M Dull, Daniela Toneatto, A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Human Vaccines & Immunotherapeutics Vol. 10, Iss. 7, 2014.
12. Erlandson and Mackey (1958) J Bacteriol 75 (3): 253-7.
13. US 5,681,736.
BE2017 / 5464
14. Uyttendaele et al. (2001) International journal of food microbiology 70 (3): 255-65.
15. Formal SB, Kent TH, May HC, Palmer A, Falkow S, LaBrec EH. Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine. J Bacteriol. 1966; 92: 17-22.
16. Makino S, Sasakawa C, Kamata K, Kurata T,
Yoshikawa required for
High yield membrane
M. A genetic determinant continuous reinfection of adjacent cells on large plasmid in S. flexneri 2a. Cell. 1986; 46: 551-555.
17. Berlanda Scorza F, Colucci AM, Maggiore L,
Sanzone S, Rossi O, Ferlenghi I, et al production process for Shigella outer particles. PLoS One. 2012; 7: e35616.
18. Plum A-L, Schuch R, Fernandez RE, Mumy KL, Kohler H, McCormick BA, et al. nadA and nadB of Shigella flexneri 5a are antivirulence loci responsible for the synthesis of quinolinate, a small molecule inhibitor of Shigella pathogenicity. Microbiology. 2007; 153: 23632372.
19. Clementz T, Bednarski JJ, Raetz CR. Function of the htrB high temperature requirement gene of Escherchia coli in the acylation of lipid A. J Biol Chem. 1996; 271: 12095-12102.
20. Rossi 0, Pesce I, Giannelli C, Aprea S, Caboni M, Citiulo F, et al. Modulation of Endotoxicity of Shigella Generalized Modules for Membrane Antigens (GMMA) by Genetic Lipid A Modifications: Relative Activation of TLR4 and TLR2 Pathways in Different Mutants. J Biol Chem. 2014; 289: 24922-24935.
BE2017 / 5464
21. Micoli F, Rondini S, Gavini M, Pisoni I, Lanzilao L, Colucci AM, et al. A scalable method for 0antigen purification applied to various Salmonella serovars. Anal Biochem. 2013; 434: 136-145.
22. Robbins JB, Kubler-Kielb J, Vinogradov E, Mocca C, Pozsgay V, Shiloach J, et al. Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates. Proc Natl Acad Sci USA. 2009; 106: 79747978.
23. Westphal 0, Jann K. Bacterial lipopolysaccharides: extraction with phenol-water and further application of the procedure. 1965; 5: 83-91.
24. Stoddard MB, Pinto V, Keizer PB, Zollinger W. Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants. Clin Vaccine Immunol. 2010; 17: 98107.
25. Pyrogens. In: European Pharmacopoeia. 8th ed. Strasbourg, Cedex: Directorate for the Quality of Medicines & Healthcare of the Council of Europe (EDQM). 2013. chapter 2.6.8.
26. Moscardo E, Maurin A, Dorigatti R, Champeroux P, Richard S. An optimized methodology for the neurobehavioral assessment in rodents. J Pharmacol Toxicol Methods. 2007; 56: 239-255.
27. Jiang Y, Yang F, Zhang X, Yang J, Chen L, Yan Y, et al. The complete sequence and analysis of the large virulence plasmid pSS of Shigella sonnei. Plasmid 2005; 54: 149-159.
BE2017 / 5464
28. Rossi 0, Maggiore L, Necchi F, Koeberling Ο, MacLennan CA, Saul A, et al. Comparison of Colorimetric Assays with Quantitative Amino Acid Analysis for Protein Quantification of Generalized Modules for Membrane Antigens (GMMA). Mol Biotechnol. 2014; in press.
29. WO 99/57280
30. Tettelin et al. (2000) Science 287: 1809-1815.
31. Comanducci et al. (2002) J. Exp. Med. 195:
1445-1454.
32. WO 03/010194.
33. WO 00/66741
34. Masignani et al. (2003) J Exp Med 197: 789-799.
35. Welsch et al. (2004) J Immunol 172: 5605-15.
Hou et al. (2005) J Infect Dis 192 (4): 580-90.
37. WO 03/063766.
38. Fletcher et al. (2004) Infect Immun 72: 20882100.
39. Zhu et al. (2005) Infect Immun 73 (10): 6838-45.
40. Cantini et al. (2006) J. Biol. Chem. 281:
7220-7227
41. Madico et al. (2006) J Immunol 177: 501-10.
42. WO 2004/048404
43. Espevik and Niessen, 1986, J. Immunol. Methods 95: 99-105;
44. Ziegler-Heitbrock et al 41: 456-461
1988, Int. J. Cancer
BE2017 / 5464
Example B
In a second strategy, the fHbp and NHBA lipoproteins from N. meningitidis MC58 were cloned into the plasmid pETCOLA (which has 2 cloning sites for the coexpression of genes of interest) under the control of a promoter inducible by IPTG either alone or simultaneously with NMB0313 and expressed in a non-pathogenic strain of Escherichia coli, or with the coexpression of NMB0313.
The strain of E. coli BL21 (DE3) was transformed with the empty petCOLA or petCOLA plasmid carrying fHbp, nhba or nmb0313 alone or pETCOLA carrying NHBA and nmb0313 or fHbp and nmb0313, respectively (Figure 7).
The expression levels of all the proteins responded to IPTG induction (data not shown) and the expression of the two lipoproteins was confirmed by a Western Blot analysis (FIG. 8). Expression of fHbp and NHBA in total lysates from E. coli coexpressing NMB0313 was superior to E lysates. coli expressing only lipoproteins (Figure 8). This confirms that the presence of NMB0313 has a positive effect on the expression of fHbp and NHBA in the heterologous system of E. coli. FACS analysis revealed that NMB0313 is necessary for surface exposure of both NHBA and fHbp (two lipoproteins from N. meningitidis). While expression in total lysates was clearly detectable by Western blot, no fHbp or NHBA was detectable on the surface when NMB0313 is not coexpressed.
BE2017 / 5464
We have generated OMV from 6 different strains of E. coli expressing different both with and lipoproteins of N. meningitidis, without coexpression of NMB0313, which led to their differential expression on the surface. After the purification of OMV from E. coli, a PAGE on SDS gel was performed to characterize the preparation. The OMVs of E. coli were enriched with N. meningitidis proteins (NMB0313, fHbp and NHBA) which are visible from the PAGE on SDS gel (Figure 9). In particular, the differences in the amount of fHbp and NHBA in OMVs from cultures when expressed alone or co-expressed with NMB0313 have been evident. The two lipoproteins are present in greater amounts in OMVs from cultures with coexpression of NMB0313 and lane 6 against summer (lane 4 against lane 3, lane 5).
After purification of OMV from E. coli, yields for all preparations quantified. The evaluation of the preparation yields reveals an increase in the quantity of OMV purified from the strains of E. coli expressing N. meningitidis proteins, in particular for fHbp and NMB0313. As shown in the table below, the OMVs from the E. coli that do not express proteins (empty) have the lowest OMV recovery. This suggests that the overexpression of these proteins of the outer membrane leads to the formation of recombinant strains of "hyperblebs" of E. coli.
BE2017 / 5464
Concentrationpg / pl Yield(mg / 1) Empty 0.344 1,769 0313 2, 694 13,085 fHbp 0.982 10,381 fHbp + 0313 1.851 19, 566 NHBA 0.639 4, 932 NHBA + 0313 0.484 3,740
OMVs from E. coli coexpressing fHbp and NMB0313 contain high amounts of fHbp, where it appears to be the most abundant protein in OMV. In order to better quantify the difference in total amount of fHbp in the OMVs prepared from cultures expressing fHbp alone or with NMB0313, the WB analysis using a serial dilution of the OMVs was carried out (FIG. 10). The coexpression of fHbp and NMB0313 resulted in more than 10 times more fHbp than the expression of fHbp alone.
These OMV preparations were included in an immunization schedule (Figure 11). The study tested whether the coexpression of NMB0313 with meningococcal lipoproteins in a heterologous context of E. coli has an effect on the immunogenicity of the resulting OMVs. CD1 mice were immunized intraperitoneally with the indicated doses of OMV (i.e.
2 pg or 0.2 pg) twice on day 1 and on day 21, and the final blood sample was taken on day 35. The recombinant fHbp and NHBA (1 pg) were used as positive controls.
BE2017 / 5464
ELISA titers using recombinant fHbp as a sensitizing antigen (Figure 12) on sera from groups 1 to 7 revealed that the OMV formulations carrying fHbp, with the exception of 0.2 pg d Carrying fHbp alone, triggered antibody titers which were significantly higher than negative controls (empty OMV and OMV-0313) Immunizations with 1 pg of recombinant fHbp resulted in IgG titers similar to immunizations with 2 pg d 'OMV-fHbp and 0.2 µg OMV-fHbp + 0313. There is a trend for dose-dependent anti-fHbp titers with fHbp-carrying OMVs
alone (FHBP; î but any difference apparent between the 2 doses from OMV with a both the fHbp and NMB0313 (FHBP + 0313). For measure the answers in antibody
functional, we carried out bactericidal activity tests of the sera with rabbit complement (rSBA) on the grouped sera coming from groups 1 to 7 on the strain to be tested H44 / 76 fHbp (FIG. 13). No destruction was obtained with the control serum. Surprisingly, the grouped sera derived from all immunizations including 0.2 μg of OMV carrying fHbp alone, show a high bactericidal activity. The pooled sera from groups immunized with 2 µg of OMV carrying fHbp alone, and the two doses of OMV carrying fHbp and NMB0313 gave higher titers compared to 1 µg of rfHbp vl.1.
Performing the rSBA test using simple mouse sera (Figure 14) confirmed the
BE2017 / 5464 results obtained with pooled sera (Figure 14). Interestingly, the titers of 6 out of 8 mice from immunizations (2 pg and 0.2 pg) of OMV with fHbp and NMB0313, were above the quantifiable technical limit in these experiments (titles> 524288). In general, the functional bactericidal responses triggered from OMV formulations when fHbp is coexpressed with NMB0313 are superior to responses with recombinant protein, and at equivalent doses of OMV with expressed fHBP alone. In conclusion, all preparations are capable of producing antibodies against fHbp including 1 µg of recombinant fHbp. Nevertheless, the fHbp expressed on the OMV of E. coli in a native conformation is capable of triggering higher bactericidal titers compared to 1 µg of recombinant fHbp. These OMV formulations resulting from the coexpression of NMB0313 with fHbp show the highest bactericidal responses with both the high doses (2 pg) and low doses (0.2 pg) resulting in responses above the quantifiable range of dilutions performed here. These data confirm that the coexpression of NMB0313 with model lipoproteins such as fHbp can significantly improve the immunogenicity of OMV preparations.
ELISA titers using recombinant NHBA as sensitizing antigen (Figure 15) from sera from groups 1, 2, 8, 9 and 10 revealed that all preparations comprising NHBA triggered antibody titers who were significantly superior to the negative controls (OMV
BE2017 / 5464 empty and OMV-0313). Sera from mice immunized with OMV-NHBA + 0313 show higher antibody titers compared to sera from mice immunized with OMV with only NHBA expression, and show a tendency to be superior to mice immunized with 1 µg of NHBA
The functional responses were measured using an rSBA test of the sera grouped against recombinant meningococcal strains to be tested expressing the NHBA (5/99 OE nHBAp2) or which lack the expression of the NHBA (5 / 99AnhbA) (FIG. 16). The pooled sera from the group of mice immunized with OMVs from NHBA coexpressed with NM0313 gave high bactericidal titers which were higher than those of the group immunized with 1 μg of recombinant NHBA protein. These bactericidal titers were specific to NHBA because no bactericidal response was measured against the strain to be tested which lacks the expression of NHBA. While positive IgG titers were measured by an ELISA test with OMVs expressing NHBA alone, these did not cause a functional response from the pooled sera from this group. The analysis of the bactericidal responses for the grouped sera directed against 2 other strains to be tested M4407 and NGH38 showed that the grouped sera from group 7 (OMVNHBA) did not succeed in showing bactericidal titers while the grouped sera from OMV expressing both NHBA and NMB0313 exhibited superior responses to pooled sera from
BE2017 / 5464 (Figure 17) confirms the pooled sera. The immunized group test with 1 µg of recombinant protein (Figure 16b).
Performing the rSBA test using simple mouse sera, results obtained with the
ELISA shows that the OMVs of E. coli carrying NHBA alone or with NMB0313 are capable of producing antibodies directed against NHBA, whereas no functional response was triggered by OMVs with NHBA alone. These data confirm that the coexpression of NMB0313 with NHBA significantly increases the immunogenicity of the resulting OMV compared to those prepared from the strain expressing NHBA alone.
The deletion of nmb0313 affects the surface exposure of the lipoproteins analyzed in the meningococcal strain NGH38. In particular, the absence of NMB0313 leads to undetectable levels of NHBA on the surface and, as a consequence, its accumulation within bacteria. On the other hand, decreased levels of fHbp on the surface were detected and these low levels were a consequence of a general reduction in the amount of fHbp in the context of nmb0313 KO compared to the wild type. Consequently, NMB0313 plays an essential role in the translocation of NHBA towards the surface of the bacterium but its deletion does not affect the expression of NHBA per se, however, NMB0313 contributes to the stable expression of fHbp and therefore to its expression on the surface. Then, the phenotype was restored in the NGH38 nmb0313 KO strain by genomic complementation of a copy
BE2017 / 5464 functional of the nmb0313 gene under the control of the Tac promoter inducible by IPTG (Figure 18). The complemented strain is capable of expressing NMB0313 in an IPTG-dependent manner as demonstrated by Western blot, and the highest concentrations of IPTG induce an overexpression of the NMB0313 protein.
To test how the differential SLPs exposed on the OMV delivery system as a function of the modified guantité of NMB0313 direct differential immune responses against these SLPs, OMVs from NGH38 strains were produced. OMVs from WT, Δ0313 and C10313 with 0.1 mM IPTG were purified and analyzed by WB and PAGE on SDS gel. The overexpression of NMB0313 is visible in the complemented strain, but there is no other significant difference in the SDS-PAGE profile of the proteins (FIG. 19). These OMVs were used for the immunization of mice and the rSBA analysis was carried out on the sera grouped with 3 strains to be tested. The rSBA analysis shows a trend for reduced SBA titers from these meningococcal OMVs prepared in l absence of constitutive expression (WT) and inducible expression (Ci0313) and, consequently, of destructive activity in these immunized groups. This confirms the role of NMB0313 in the direction of bactericidal activity also in a homologous system.
The differences in bactericidal titers were reduced in the sera produced from immunization with the preparation NGH38A0313, then
BE2017 / 5464 that the titles of NGH38 C10313 show a bactericidal activity comparable to the NGH38 WT strain (FIG. 20). The rSBA analysis using the reference strain 5/99 OE NHBAp2 and the corresponding ΔΝΗΒΑ strain also shows that this immunogenicity is not exclusively directed by NHBA. Presumably, other lipoproteins undergo translocation on the surface in an NMB0313-dependent fashion, and these SLPs may have affected immunogenicity.
These data confirm a role for NMB0313 in the immunogenicity of meningococcal OMVs in that expression of NMB0313 in a meningococcal vaccine strain leads to preparations of OMV with higher immunogenicity.
Materials and processes
Bacterial strains and culture conditions
The Neisseria meningitidis (Nm) strains from serogroup B (MC58, NHGH38, NZ 98/254 and its isogenic derivatives) and the Escherichia coli (Ec) strains (DH5a and BL21-DE3) used in this study are listed.
The N. meningitidis strains were cultured on agar plates of gonococcal base medium (GC) (Difco) or in GC broth at 37 ° C in 5% CO2.
The strains of E. coli were grown in LB agar or LB broth at 37 ° C.
Antibiotics were added when necessary. Kanamycin and chloramphenicol were added at final concentrations of 150 pg / ml and 5 pg / ml for selection of mutants by deletion.
BE2017 / 5464 and N. meningitidis complementing strains, respectively.
Ampicillin, kanamycin, or chloramphenicol was added at final concentrations of 100, 150 or 10 pg / ml for the selection of E. coli.
When necessary, isopropyl-β-D1-thiogalactopyranoside (IPTG) (1 mM) (Sigma) was added to the culture medium at the final concentrations indicated.
Construction of strains mutants and of complementation The manipulations of DNA have summer carried out in routine as it is describes for of processes
conventional in the laboratory [4].
To construct a mutant by deletion of NMB0313, the nmb0313 gene was replaced by a kanamycin cassette by double crossing over. To achieve this, the plasmid pGEMTUD313Kan was produced as follows. The flanking regions upstream and downstream of nmb0313 were amplified from the chromosome of MC58 with restriction enzyme sites and cloned into the plasmid pGEMT. The kanamycin cassette was cloned as a 1.4 kb Xbal fragment in the Xbal site between the two flanking regions. This plasmid was used to transform the strains of N. meningitidis.
The complementation of nmb0313 was obtained by insertion of a copy of nmb0313 in the non-coding region between the convergent ORFs NMB1428 and NMB1429 of the chromosome of the Δ0313 strains. To achieve this, the
BE2017 / 5464 plasmid pComPIndNMB0313 was produced by amplification of the nmb0313 gene and cloned in the form of an Asel / Nsil fragment under the control of the inducible promoter Tac and the repressor Lacl in the plasmid pComPInd [5].
The primers and plasmids are listed in the attached tables.
The correct nucleotide sequence of each plasmid was confirmed by DNA sequencing.
The plasmids were linearized and used for the transformation of the strains of N. meningitidis.
All transformants were verified by both PCR and Western blot analysis.
Western blot analysis
Overnight cultures on agar plates were resuspended in GC to 0.5 DCCoo / ml. One milliliter of the resuspension was centrifuged for 5 min at 13,000 rpm and the pellet was resuspended in 100 μΐ of SDS loading buffer (50 mM Tris-HCl [H 6.8], 2.5 % of
SDS, 0.1% bromophenol blue, 10% glycerol, 5% 3-mercaptoethanol, 50 mM DTT) [6].
In the case of liquid cultures, the strains were cultured up to 0.5 DCGoo / ml and one milliliter of the culture was aggregated and resuspended in 100 μΐ of SDS loading buffer. The protein extracts were separated by SDS-PAGE on NuPAGE® Novex® 4-12% Bis-Tris Protein Gels gels in MES IX (Life Technologies) and then transferred to nitrocellulose membranes. The membranes have been
BE2017 / 5464 blocked overnight at 4 ° C with PBS + 0.05% Tween 20 (Sigma) and 10% milk powder (Sigma).
The primary antibody was diluted as reported in the antibody table in PBS + 0.05% Tween 20 and 3% milk powder and incubated for 1 h with the membrane. Anti-mouse IgG antibody conjugated to horseradish peroxidase (HRP) and the Western Lightning ECL reagent (Perkin Elmer) were used according to the manufacturer's instructions for detection.
Fluorescence Activated Cell (FACS) Sorting Analysis of fHbp Expression
The strains of N. meningitidis and their isogenic derivatives were collected after liquid cultures at DChoo of 0.5, when necessary, IPTG was also added. The bacteria were inactivated by incubation with 0.5% formaldehyde for 1 hour at room temperature.
Labeling was carried out with the primary antibody diluted in PBS-0.5% BSA (Sigma) as reported in the table.
The binding of the primary antibody was detected using an anti-mouse antibody (whole molecule) conjugated to FITC (Sigma) at the correct dilution.
Bactericidal serum activity test (SBA)
Day 1 :
Spread the bacteria from the frozen stock on a round chocolate agar plate and incubate for 18 hours at 37 ° C with 5% CO2.
Day 2:
BE2017 / 5464
Inoculate 7 ml of Mueller Hinton broth (MHB) with 0.25% (w / v) glucose, with bacteria up to DOsoo = 0.05, white = MHB
Incubate the 7 ml of bacteria in a shaker at 150 rpm at 37 ° C with 5% CO2
Stop the incubation when the DCPoo = 0.24 to 0.26 (approximately 2 to 4 x 10 ⁸ CFU / ml), normally after 1.5 to 2 hours
Perform a working dilution of the bacteria in a test buffer of 2 to 4 x 10 ⁴ CFU / ml (1 / 10,000) by diluting the bacteria in two steps (i.e., 10 μΐ of the bacterial culture in 1 ml of buffer, 100 μΐ of this suspension in 10 μΐ of buffer) to arrive at a final dilution of 1/10 000.
Dilution of the sera:
Fill the wells of the sterile round bottom plate with 96 wells from column A to G with 25 ml of buffer and the wells from column H with 20 ml.
Columns A to F are for the dilution of the sera: add 25 ml of serum sample to the first well of each row and carry out a serial dilution to half. The final volume in columns A to G is now 25 ml / well.
Add 5 ml of sample and 12.5 ml / well of inactivated complement to column H.
Columns G and H represent the negative experimental controls: column G is the complement control, contains buffer, bacteria and active complement, column H is the serum control, contains buffer, bacteria, serum and inactivated complement.
BE2017 / 5464
Add 12.5 ml / well of bacteria at the working dilution to all the wells in columns A to H.
Add 12.5 ml / well of active complement to each well in columns A to G.
Homogenize by stirring the microtiter plate.
Immediately after the addition of the complement, take 10 ml of reaction from the negative control wells of G and H and spread in streaks on square plates of Mueller-Hinton agar (HD agar) using the oscillation process, moment represents time zero (t = 0). Incubate the 96-well plate with the reaction at 37 ° C with 5% CO2.
After 60 minutes (t = 60), take 10 ml of the negative control wells from columns G and H and spread in streaks on agar plates using the oscillation method. Place 7 ml of each sample well in duplicate on square Petri dishes with HD agar using 12-channel multichannel pipettes (1 to 50 ml). Incubate overnight at 37 ° C with 5% CO2.
Day 3:
Count the quantity of colonies in the controls at t = 0 and t = 60.
Count the amount of colonies in the square plates with the deposits.
Calculate the number of colonies that represent the 50% destruction.
Bactericidal titer = the dilution of the serum which destroys 50% of the bacteria added at time zero.
Serum analysis - ELISA
BE2017 / 5464
100 μΐ of 0.015 μΜ antigen were added to each well of a 96-well Nunc Maxisorp plate and incubated overnight at 4 ° C.
The wells were then washed three times with washing buffer (PBT).
250 μΐ of saturation buffer (PVP) were added to each well and the plates were incubated for 2 hours at 37 ° C.
The wells were washed three times with PBT.
100 μΐ of diluted sera were added to each well and the plates were incubated for 2 hours at 37 ° C.
The wells were washed three times with PBT.
100 μΐ of the sera from secondary antibodies conjugated with alkaline phosphatase diluted to 1/2000 in dilution buffer were added to each well and the plates were incubated for 90 minutes at 37 ° C.
Wells were washed three times with buffer
PBT.
100 μΐ of p-nitrophenyl phosphate substrate were added to each well and the plates were left at room temperature for 30 minutes.
100 μΐ of 4N NaOH were added to each well and the OD at 405 / 620-630 nm was followed.
Antibody titers were quantified by interpolation against a reference standard curve.
Reagents:
1) Nunc Maxisorp plate Code 442404
BE2017 / 5464
2) 2.7% polyvinylpyrrolidone saturation buffer (PVP) in water
3) Wash buffer (PBT) 0.05% Tween-20, in 0.074 M PBS
4) Dilution buffer: 1% BSA, 0.05%
Tween-20, in 0.074 M PBS
5) Secondary antibodies conjugated to alkaline phosphatase Sigma Code A3562
6) p-nitrophenyl phosphate substrate (pNPP) Sigma code P 7998
7) antigen buffer (0.148 M). Na ₂ HPO ₄ 1.15 g. KC1 0.2 g. KH2PO4 0.2 g. NaCl 8.0 g. pH 7.4 ± 0.1. Distilled water qs 1 liter
Isolation of external membrane vesicles (OMV) native to Neisseria meningitidis
Culture of strains • Inoculate the desired strain the day before the experiment on a GC agar plate • Inoculate a 250 ml shaking flask containing 50 ml (MCDMI) with the starting culture up to an OD600 of 0.15 at 0.25 • Incubate the flask at 37 ° C, 0% CO2 and
160 rpm to stationary phase (approximately overnight) • Evaluate OD / ml (necessary for yield) and take samples for Wb and FACS analyzes (if necessary)
BE2017 / 5464 • Transfer the cultures to 50 ml Falcon tubes • Centrifuge the cultures at 3500 rpm for 30 min at 4 ° C • Remove the baskets from the centrifuge and transfer to a biosafety cabinet • Transfer the supernatant to 125 ml Stericup filter bottles (0.22 µm pore size) and filter.
• Take 100 μΐ of the filtered supernatant and place it on a GC agar plate as a control for the elimination of Neisseria • Store the bottle at 4 ° C until confirmation of the inactivation / elimination of bacteria in the supernatant filtered after 24 to 48 hours of incubation of the control agar plates • The filtered supernatants can be considered sterile if the plates covered with the filtered supernatant show no growth AND that the plates with the cultures after incubation show growth
Culture of E. coli BL21 • Inoculate the desired strain the day before the experiment on an LB Kan plate • On the day of the experiment, deposit a few colonies on LB + Kan and growth day 0 180 rpm, 37 ° C • Inoculate at 1 / 100 in a vial containing 50 ml (HTMC) with kanamycin (50 pg / ml) and IPTG (0.1 mM)
BE2017 / 5464 • Incubate the flask at 30 ° C and 160 rpm until the stationary phase (approximately overnight)
Evaluate the OD / ml (necessary for yield) and take samples for Wb and FACS analyzes (if necessary)
Transfer cultures to 50 ml Falcon tubes
Centrifuge cultures at 3,500 rpm for 30 min at 4 ° C
Transfer the supernatant to 125 ml Stericup filter bottles (pore size of
0.22 pm) and filter • Store the stages bottle
Preparation of nOMVs filtered at 4 ° C to the others from the supernatants • Transfer the filtered supernatant to 70 ml ultracentrifuge tubes (suitable for a 45Ti centrifuge) and fill any empty tube space with PBS • Centrifuge the samples at 35,000 rpm (96,000 xg, average) and 4 ° C. for 2 hours • Washing step with PBS • Carefully remove the supernatant • Resuspend the pellet in 200 to 500 μl of PBS (protease inhibitors can be added to the buffer at this point) • Optionally, the pellet can be left immersed in the buffer overnight
BE2017 / 5464 • Store the pellets at -20 ° C until another analysis
Analysis of nOMV preparations
Determination of protein concentration • Determine protein concentration using the BioRad DC kit • Use a protein calibration curve of 2 to 0.06 mg / ml (three replicates) • Make appropriate dilutions of OMV samples (up to 1/10, up to 1/100 for high efficiency isolation; pellet size) • Measure the absorbance at 750 nm in a plate reader using the measurement of the final criterion • Calculate the concentration proteins using both a linear and best-fit relationship
Determination of the composition of nOMVs • Resuspend the specific amount of nOMVs with SDS 2X loading buffer (final volume of 10 to 15 μΐ) • Pass the protein sample on an SDS-PAGE gel using MES buffer • Take 1 pg of total nOMV for WB analysis, transfer the gel and develop using a specific antibody • Take 5 to 10 pg of nOMV for SDS-PAGE on gel using either SimplyBlue
BE2017 / 5464
SafeStain is a protein protein stain with silver
BE2017 / 5464
Table ofstrains Last name Description Cassette ofresistance toantibiotic Reference Strains of N. meningitidis NGH38 Wt strain ofNeisseriameningitidis NGH38 Δ0313 Derived from NGH38,insertion ofkanamycin in thenmb0313 locus Kanamycin Thisstudy NGH38 Δ0313ci0313 Derived from NGH38, atwhich is missingthe nmb0313 genewith a copy ofnmb0313reintroduced inoutside the locusunder the pTACinducible byThe IPTG Chloramphenicol Thisstudy Strains of. coli DH5a fhuA2 lac (del) U169phoA glnV44 Φ80 'lacZ (del) Ml 5 gyrA96recAl relAl endAlthi — 1 hsdRl7 BL21 (DE3)
BE2017 / 5464
Table ofstrains Last name Description Cassette ofresistance toantibiotic Reference pCOLA DUET Vector codefor two sites ofmultiple cloning,with the promoterT7, the repliconCOLA by ColA, thelacl repressor andKanR Kanamycin Novagen pGEM-T Cloning vectorof. coli, AmpR Ampicillin Promega pComP _IND CmR Plasmid for thereplacementallelic at the levelof a locationchromosomal betweenORF NMB1428 andNMB1429 andexpressioninducible under thecontrol ofPTAC promoter andof the lacl repressor.Upstream of the sitecloning there is acassetteresistance to cm Ampicillin,Chloramphenicol leva, R.,et al. JBacteriol,2005.
BE2017 / 5464
Table ofstrains Last name Description Cassette ofresistance toantibiotic Reference pUD0313Kan pGEM-T containing theflanking regionfrom nmb0313 with thecassetteresistance to Kancloned under theshape of a fragmentXmal betweenflanking regions Ampicillin,Kanamycin Thisstudy pIND0313 Plasmid forcomplementation ofnmb0313 in theCorn region with atac promoterinducible bythe IPTG. Downstream ofnmb0313, acassetteresistance to cmis cloned. Ampicillin,Chloramphenicol Thisstudy pCOLA_0313 Construction forexpress theproteinrecombinantNMB0313 fromN. meningitidisin E. coli Kanamycin Thisstudy
BE2017 / 5464
Table ofstrains Last name Description Cassette ofresistance toantibiotic Reference pCOLA NHBA Construction forexpress theproteinrecombinantNMB2132 ofN. meningitidisin E. coli Kanamycin Thisstudy pCOLA fHbp Construction forexpress theproteinrecombinantNMB1870 fromN. meningitidisin E. coli Kanamycin Thisstudy pCOLA NHBA 0313 Construction forcoexpress themproteinrecombinantNMB0313 and NMB2132from N. meningitidisin E. coli Kanamycin Thisstudy pCOLA fHbp 0313 Construction forcoexpress themproteinrecombinantNMB0313 and NMB1870from N. meningitidisin E. coli Kanamycin Thisstudy
BE2017 / 5464
Table of primers Name of Application Sequence The primer 0313UP_F Fragment for theproduction of 0313 KOin MenB with the siteXbal restriction GagatctagaGCCGGcattcgggcaaaaaccSEQ ID NO: 14 0313UP_R Start of merger inupstream and downstream offlank of NMB0313 withthe restriction siteXmal AACAGCAACCCGGGTATCAATCGGCG GATSEQ ID NO: 15 NMB0313 FW DO Initiation of merger inupstream and downstream offlank of NMB0313 withthe restriction siteXmal CCGATTGATACCCGGGTTGCTGTTCC TTTTCGSEQ ID NO: 16 NMB0313 RV UP Initiation of merger inupstream and downstream offlank of NMB0313 withthe restriction siteXmal AACAGCAACCCGGGTATCAATCGGCGGATSEQ ID NO: 17 0313pC_F Cloning of the geneNMB0313 in theplasmid pCOM for thecomplementation inMENB NM0313KO GtgtattaatatggttattttttatttttgtgSEQ ID NO: 18 0313pC_R Cloning of NMB0313 inthe plasmid pCOM forcomplementation inMENB NM0313KO GtgtatgcattcagaacgttttattaaactcSEQ ID NO: 19
BE2017 / 5464
Table ofprimers Name ofThe primer Application Sequence Î313F2 Cloning of the geneNMB0313 in MCS2 ofpCOLA with the site ofMfel restriction GCAGATCTCAATTGatggttattttttatttttgtgSEQ ID NO: 20 Î313R2 Cloning of the geneNMB0313 in MCS2 ofpCOLA with the site ofXhol restriction TTACCAGActcgagtcagaacgttttattaaacyouSEQ ID NO: 21 iPCR fhbp MCS Cloning of the gene AGCATTATgcggccgcTTATTGCTTGGC 1 R V NMB1870 in MCS1 frompCOLA GGCAAGSEQ ID NO: 22 iPCR fHBP MCS Cloning of the gene GGAGATATAccatggTGAATCGAACTG l_ (ifHbpl_2) NMB1870 in MCS1 frompCOLA CCTTCTGSEQ ID NO: 23 iPCR NHBA MCS Cloning of the gene GGAGATATAccatggTCTTTAAACGCA 1 FW NMB2132 in MCS1 of GCGTAATC (iNHBAl 2) pCOLA SEQ ID NO: 24 iPCR NHBA MCS Cloning of the gene AGCATTATgcggccgcTCAATCCTGCTC 1 RV NMB2132 in MCS1 ofpCOLA TTTTTTGCSEQ ID NO: 25
BE2017 / 5464
Antibody table DilutionWB DilutionFAC S Seruma-fHbp polyclonal of mouse 1/5000 1/1000 Serum polyclonal of mouse 1/2000 1/800 a-NHBA Serum monoclonal of mouse 1/4000 1/1000 a-NHBA a-mouse-FITC 1/1000 a-mouse-HRP 1/1000
BE2017 / 5464
References
1. Schwechheimer, C. membrane vesicles from biogenesis and functions.
and M.J. Kuehn, Outer Gram-negative bacteria
Nat Rev Microbiol, 2015 (10): p. 605-19.
2. Fantappie, L., et al. , Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen. J Extracell Vesicles, 2014. 3.
3. Yogesh Hooda, CC-LL, Andrew Judd, Carolyn M. Buckwalter, Hyejin Esther Shin, Scott D. Gray-Owen and Trevor F. Moraes, Slam is an outer membrane protein that is required for the surface display of lipidated virulence factors in Neisseria. Nature microbiology, 2016. 1.
4. Sambrook J, F.E., Maniatis T, Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, 1989. 2nd ed.
5. leva, R., et al. , CrgA is an inducible LysRtype regulator of Neisseria meningitidis, acting both as a repressor and as an activator of gene transcription. J Bacteriol, 2005. 187 (10): p. 3421-30.
6. Oriente, F., V. Scarlato, and I. Delany,
Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNRregulated promoter. J Bacteriol, 2010. 192 (3): p. 691701.
BE2017 / 5464

权利要求:
Claims (17)
[1]
1. Gram negative “hyperbleb” bacteria which overexpress, express constitutively or inducibly express a flippase.
[2]
2. Gram negative “hyperbleb” bacterium according to claim 1 which is chosen from the group consisting of Neisseria, Salmonella, Shigella, Haemophilus, Bordetella, Moraxella and Escherichia.
[3]
3. Gram negative “hyperbleb” bacterium according to claim 2 which is chosen from the group consisting of Neisseria meningitidis, Neisseria gonorrhoeae, Salmonella typhi, Salmonella typhimurium, Shigella flexneri, Shigella dysenteriae, Shigella boydii, Shigella sonnei, Haemophilus influenzae, Haemophilus influenzae Escherichia coli.
[4]
4. Gram negative “hyperbleb” bacterium according to claim 3 which is a strain of Neisseria meningitidis or Neisseria gonorrhoeae which has been genetically modified by negative regulation of the expression of GNA33.
[5]
5. Gram negative “hyperbleb” bacterium according to claim 4 which has been genetically modified by mutation of at least one gene chosen from the group consisting of IpxL1, synX and IgtA.
[6]
6. Gram negative “hyperbleb” bacterium according to claim 3 which is a strain of Haemophilus influenza, Moraxella catarrhalis or Escherichia coli which has been genetically modified by down regulation of one or more genes chosen from the group consisting of tolQ, tolR, tolX, tolA and tolB.
BE2017 / 5464
[7]
7. Gram negative bacterium “hyperbieb” according to claim 3 which is a strain of Shigella flexneri, Shigella dysenteriae, Shigella boydii or Shigella sonnei which has been genetically modified by negative regulation of tolR or OmpA.
[8]
8. Gram negative bacterium "hyperbieb" according to claim 7 which has been genetically modified by mutation of at least one gene selected from the group consisting of htrA, msbBl, msbB2 and virG.
[9]
9. Gram-negative “hyperbieb” bacterium according to any one of the preceding claims which has been genetically modified by one or more methods chosen from the following group: (a) a method for the negative regulation of the expression of immunodominant antigens variable or non-protective, (b) a method of positive regulation of the expression of protective OMV antigens, (c) a method of negative regulation of a gene involved in making the lipid A part of LPS toxic, (d ) a method of upregulating a gene involved to make the lipid A part of the LPS less toxic, and (e) a method of genetic modification of the bacterium to express a heterologous antigen.
[10]
10. Gram-negative “hyperbieb” bacterium according to any one of the preceding claims, in which the flippase comprises a sequence having 80% of sequence identity with a sequence chosen from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4.
BE2017 / 5464
[11]
11. Preparation of outer membrane vesicles obtained from the bacterium as defined in any one of claims 1 to 10.
[12]
12. Preparation of membrane vesicles according to claim 11 which can be filtered through a 0.22 µm membrane.
[13]
13. A pharmaceutical composition comprising the preparation of outer membrane vesicles according to claims 11 and 12 together with a pharmaceutically acceptable diluent or carrier.
[14]
14. Pharmaceutical composition according to claim 13 for use in a method of treatment of the human or animal body.
[15]
15. A method of protecting an individual against a bacterial infection which comprises administering to the individual an effective amount of the preparation as defined in any one of claims 11 to 14.
[16]
16. A method of preparing a pharmaceutical composition comprising a preparation of outer membrane vesicles as defined in claims 11 and 12, the method comprising: (a) inoculating a culture vessel containing a nutritive medium suitable for growing the bacteria according to any of claims 1 to 10; (b) culturing said bacteria; (c) recovering the outer membrane vesicles from the medium; and (d) mixing the outer membrane vesicles with a pharmaceutically acceptable diluent or carrier.
BE2017 / 5464
[17]
17. The method of claim 16 which further comprises a step after either step (c) or step (d) comprising sterilization by filtration of the preparation of outer membrane vesicles.
18. A method of producing a "hyperbleb" bacterium according to claim 1, which method comprises genetic modification of a Gram negative bacterial strain by: (a) modification of the strain to negatively regulate the expression of one or more of
Several Toi genes; and (b) modification of the strain to overexpress, express constitutively or express inducibly a flippase.
100
BE2017 / 5464
Request sequence
Specific Hits SuperÊndHes
Muliî-doiuaines
3 ft & Πί ί, 'ί φ W
I I <! I I <. I ί 1 I I (I I i I »I i I ί I I ί> I
JLA
Strain of
N. MeiiÎUgîtïâîS
UP i kauft DO <..... mnbÛ313 w ♦ UP kanft OF
TtGUß. £ d-B
101
BE2017 / 5464
MC58, N $ *} ί
0313 -
NGH38
Λ & &
A, ς £> cS ⁵
V V y V
0313
NZ 98/254
0313 * 1 • sissate "-„ "W"
F i 6 * 0 ÙB
102
BE2017 / 5464
103
BE2017 / 5464
NGH3 8 Δ0313 pComPind0313
IPTG / ///// κ cv> -Pp-Cv-Çv-CS ^ .Ôv (/ (/ (/ / / / (/
0313 χΛί * &
Τι 6ιΜε Μ ß
104
BE2017 / 5464
Fi Gute 5 A
E £ co
CO
X
O
X t
CM a
<
- - = h £ ^ S E ^ o-é £ r-ς θ O G * - cd 'o Ο Ο + + + 4- + rtrtfbfO fb rtnrûib c> - o o O O O O
CL
Q <c m
x
G.
X3
X cÛ m
at
105
BE2017 / 5464
106
BE2017 / 5464 r-4 ljO o
-3co m
GO
ΓΝ
107
BE2017 / 5464
0, OlmMIPTG 0 _t 01mM IPTG
108
BE2017 / 5464

类似技术:

---

公开号 | 公开日 | 专利标题

---

Bishop et al.2010|Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility

---

Tzeng et al.2000|Epidemiology and pathogenesis of Neisseria meningitidis

---

RU2432962C2|2011-11-10|Vaccines with application of vesicles based on gna 1870 of broad spectrum of action for prevention of diseases, caused by neisseria meningitidis

---

US8889121B2|2014-11-18|Bacterium comprising a regulated rfaH nucleic acid

---

JP2005527240A|2005-09-15|Attenuated Listeria species and how to use them

---

BE1024361B1|2018-02-05|IMMUNOGENIC COMPOSITION

---

Hu et al.2017|Vi capsular polysaccharide: Synthesis, virulence, and application

---

US20200384096A1|2020-12-10|Immunogenic compositions

---

AU734532B2|2001-06-14|Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability

---

US9597386B2|2017-03-21|Outer membrane proteins of Histophilus somni and methods thereof

---

US20150050311A1|2015-02-19|Novel method for the preparation of a strain-adapted vaccine

---

BE1024794B1|2018-07-10|IMMUNOGENIC COMPOSITIONS

---

US5698438A|1997-12-16|Bacterial hemoglobin receptor gene

---

KR20150048771A|2015-05-07|A novel live attenuated shigella vaccine

---

US8647640B2|2014-02-11|Vaccine compositions and methods of use to protect against infectious disease

---

BE1024282A1|2018-01-11|IMMUNOGENIC COMPOSITIONS

---

EP2429576A1|2012-03-21|Meningococcal vaccine based on lipooligosaccharide | and neisseria meningitidis protein

---

CA2761924C|2017-10-31|Menigococcus vaccine containing lipooligosaccharide | from modified strains of l6 immunotype neisseria meningitidis

---

Borghi2017|Investigating the molecular mechanisms of Neisseria meningitidis antigen regulation: determining a switch between colonization and invasion

---

US6277382B1|2001-08-21|Hemoglobin receptors from neisseriae

---

Muthuramalingam et al.2021|The Shigella Type III Secretion System: An Overview from Top to Bottom. Microorganisms 2021, 9, 451

---

WO2021102505A1|2021-06-03|Immunogenic protein against gonococcal infection

---

De Santis2015|Bacterial lipoproteins: sorting mechanisms and biotechnological applications

---

Weimer2009|Development of a flagellin-based multivalent vaccine against Pseudomonas aeruginosa

---

Tam2005|Rapid inversion of the Salmonella enterica shufflon: A new molecular mechanism for control of pathogenesis

同族专利:

---

公开号 | 公开日

---

EP3263695A1|2018-01-03|

---

US20200023051A1|2020-01-23|

---

BE1024794A1|2018-07-02|

---

EP3478823A1|2019-05-08|

---

WO2018002270A1|2018-01-04|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

WO2002062378A2|2001-02-08|2002-08-15|Smithkline Beecham Biologicals S.A.|Hyperblebbing bacterial strains and use thereof for production of vaccines|

---

WO2006046143A2|2004-10-29|2006-05-04|Novartis Vaccines And Diagnostics Srl|Immunogenic bacterial vesicles with outer membrane proteins|

---

WO2009158142A1|2008-05-30|2009-12-30|The U.S.A., As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army|Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof|

---

WO2011036564A2|2009-09-28|2011-03-31|Novartis Vaccines Institute For Global Health Srl|Hyperblebbing shigella strains|

---

US5679564A|1994-10-05|1997-10-21|Antex Biologics, Inc.|Methods for producing enhanced antigenic campylobacter bacteria and vaccines|

---

US5997881A|1995-11-22|1999-12-07|University Of Maryland, Baltimore|Method of making non-pyrogenic lipopolysaccharide or A|

---

AU761780B2|1998-05-01|2003-06-12|Glaxosmithkline Biologicals Sa|Neisseria meningitidis antigens and compositions|

---

CA2348928C|1998-11-03|2010-01-26|De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur|Lps with reduced toxicity from genetically modified gram negative bacteria|

---

NZ581940A|1999-04-30|2011-07-29|Novartis Vaccines & Diagnostic|Conserved neisserial antigens|

---

GB0103170D0|2001-02-08|2001-03-28|Smithkline Beecham Biolog|Vaccine composition|

---

MXPA04000653A|2001-07-27|2004-11-22|Chiron Srl|Meningococcus adhesins nada, app and orf 40.|

---

MX339524B|2001-10-11|2016-05-30|Wyeth Corp|Novel immunogenic compositions for the prevention and treatment of meningococcal disease.|

---

GB0227346D0|2002-11-22|2002-12-31|Chiron Spa|741|

---

SI1748791T1|2004-05-11|2010-07-30|Staat Der Nederlanden - Minister Van Vws|NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT|

---

GB0917003D0|2009-09-28|2009-11-11|Novartis Vaccines Inst For Global Health Srl|Purification of bacterial vesicles|

---

US10279026B2|2012-04-26|2019-05-07|Glaxosmithkline Biologicals Sa|Antigens and antigen combinations|WO2021108731A1|2019-11-25|2021-06-03|The Methodist Hospital|Aposome compositions and methods of use|

法律状态:
2018-08-31| FG| Patent granted|Effective date: 20180710 |

---

2020-03-27| MM| Lapsed because of non-payment of the annual fee|Effective date: 20190630 |

优先权:

---

申请号 | 申请日 | 专利标题

---

EP16177013.6A|EP3263695A1|2016-06-29|2016-06-29|Immunogenic compositions|

---

EP16177013.6|2016-06-29|

---